Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a median of 9 months, the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure was significan...
Uloženo v:
| Vydáno v: | The New England journal of medicine Ročník 384; číslo 2; s. 117 - 128 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Massachusetts Medical Society
14.01.2021
|
| Témata: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a median of 9 months, the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure was significantly lower with sotagliflozin than with placebo. |
|---|---|
| AbstractList | BackgroundSodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.MethodsWe performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor.ResultsA total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose.ConclusionsIn patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.) Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor. A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose. In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.). Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a median of 9 months, the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure was significantly lower with sotagliflozin than with placebo. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor.METHODSWe performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor.A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose.RESULTSA total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose.In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).CONCLUSIONSIn patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.). |
| Author | Riddle, Matthew C Cannon, Christopher P Bhatt, Deepak L Szarek, Michael Wilcox, Christopher S Lopes, Renato D Ponikowski, Piotr Leiter, Lawrence A Voors, Adriaan A Lund, Lars H Steg, P. Gabriel Lewis, Julia B McGuire, Darren K Komajda, Michel Lapuerta, Pablo Pitt, Bertram Testani, Jeffrey M Metra, Marco Verma, Subodh |
| Author_xml | – sequence: 1 givenname: Deepak L surname: Bhatt fullname: Bhatt, Deepak L organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 2 givenname: Michael surname: Szarek fullname: Szarek, Michael organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 3 givenname: P. Gabriel surname: Steg fullname: Steg, P. Gabriel organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 4 givenname: Christopher P surname: Cannon fullname: Cannon, Christopher P organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 5 givenname: Lawrence A surname: Leiter fullname: Leiter, Lawrence A organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 6 givenname: Darren K surname: McGuire fullname: McGuire, Darren K organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 7 givenname: Julia B surname: Lewis fullname: Lewis, Julia B organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 8 givenname: Matthew C surname: Riddle fullname: Riddle, Matthew C organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 9 givenname: Adriaan A surname: Voors fullname: Voors, Adriaan A organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 10 givenname: Marco surname: Metra fullname: Metra, Marco organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 11 givenname: Lars H surname: Lund fullname: Lund, Lars H organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 12 givenname: Michel surname: Komajda fullname: Komajda, Michel organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 13 givenname: Jeffrey M surname: Testani fullname: Testani, Jeffrey M organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 14 givenname: Christopher S surname: Wilcox fullname: Wilcox, Christopher S organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 15 givenname: Piotr surname: Ponikowski fullname: Ponikowski, Piotr organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 16 givenname: Renato D surname: Lopes fullname: Lopes, Renato D organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 17 givenname: Subodh surname: Verma fullname: Verma, Subodh organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 18 givenname: Pablo surname: Lapuerta fullname: Lapuerta, Pablo organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) – sequence: 19 givenname: Bertram surname: Pitt fullname: Pitt, Bertram organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen–University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33200892$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:145772735$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNp1kdtrFTEQxoNU7OnRR19lQQRfVie3TfZRamst9YIXfAzZ3dma425ymmQp-tcbOceKhQ6BCZPfhJnvOyIHPngk5DGFFxRk8_L9yfm7YBlwoJrfIysqOa-FgOaArACYroVq-SE5SmkDJahoH5BDzhmAbtmKnH8O2V5ObpzCL-ercj7a7NDnVF27_L167WyHGVNl_VB9wr68VN9CTOidv6zO0MZcnVo3LREfkvujnRI-2uc1-Xp68uX4rL748Obt8auLuhdM53q0AKOEsevlgHroW0a5HNq-ayVXjW2Aj9BbJgUKRZlG2jDbUqDDIHSnlOBrUu_-Tde4XTqzjW628acJ1pl96Ue5oRFNI4saa_J8x29juFowZTO71OM0WY9hSYaJhvJWK04L-vQWuglL9GWbQimlQILQhXqyp5ZuxuFmgL-q_puwjyGliOMNQsH8cc3851rh-S2-d7nYEHyORds7u57tuuY5GY-b-Q7uNy4lpEM |
| CitedBy_id | crossref_primary_10_1016_j_ejmech_2024_116706 crossref_primary_10_1016_j_jchf_2021_11_001 crossref_primary_10_3390_medicina60060912 crossref_primary_10_1007_s12325_022_02169_3 crossref_primary_10_1016_j_jacc_2024_02_009 crossref_primary_10_1080_14656566_2023_2195540 crossref_primary_10_1016_j_pharmthera_2022_108330 crossref_primary_10_1007_s40265_021_01573_3 crossref_primary_10_1038_s41572_024_00540_y crossref_primary_10_1093_eurheartj_ehad273 crossref_primary_10_1136_openhrt_2021_001936 crossref_primary_10_1002_ejhf_3292 crossref_primary_10_1007_s10741_024_10415_9 crossref_primary_10_1016_j_jchf_2021_11_006 crossref_primary_10_1016_j_rceng_2025_502300 crossref_primary_10_1111_apha_13589 crossref_primary_10_1016_j_nantod_2023_101784 crossref_primary_10_1002_ehf2_14297 crossref_primary_10_1002_ehf2_15386 crossref_primary_10_1111_dom_15085 crossref_primary_10_1093_ndt_gfae263 crossref_primary_10_1016_j_ijcard_2021_12_050 crossref_primary_10_1007_s00228_024_03631_7 crossref_primary_10_1177_02184923251352222 crossref_primary_10_1016_j_eprac_2022_05_005 crossref_primary_10_1053_j_jvca_2024_02_014 crossref_primary_10_1111_dom_16190 crossref_primary_10_26599_1671_5411_2025_01_006 crossref_primary_10_3390_healthcare12232464 crossref_primary_10_1016_j_ahj_2022_12_005 crossref_primary_10_1007_s00125_021_05529_w crossref_primary_10_14797_mdcvj_1155 crossref_primary_10_1093_ehjqcco_qcac040 crossref_primary_10_1016_j_jdiacomp_2022_108352 crossref_primary_10_1016_j_jdiacomp_2021_108052 crossref_primary_10_1016_j_jdiacomp_2021_108057 crossref_primary_10_3390_ph18081202 crossref_primary_10_1097_MD_0000000000034693 crossref_primary_10_1177_11795468251347777 crossref_primary_10_3390_jcm13010012 crossref_primary_10_3389_fcvm_2021_778284 crossref_primary_10_4103_ijcm_ijcm_210_23 crossref_primary_10_1016_j_jacc_2023_08_050 crossref_primary_10_1080_14656566_2021_1937121 crossref_primary_10_1111_jdi_13915 crossref_primary_10_26693_jmbs07_01_014 crossref_primary_10_1007_s11897_021_00529_8 crossref_primary_10_1093_ndt_gfaf132 crossref_primary_10_1056_NEJMra2115011 crossref_primary_10_1016_j_jchf_2024_01_018 crossref_primary_10_1038_s41569_025_01152_z crossref_primary_10_1093_eurheartj_ehaf229 crossref_primary_10_1111_dom_15080 crossref_primary_10_1016_j_pcd_2022_02_002 crossref_primary_10_1016_S2213_8587_24_00155_4 crossref_primary_10_1097_MD_0000000000032489 crossref_primary_10_17925_HI_2023_17_2_5 crossref_primary_10_1016_j_jacc_2024_02_012 crossref_primary_10_1016_j_jacc_2024_11_041 crossref_primary_10_1016_j_cardfail_2021_12_013 crossref_primary_10_1002_ejhf_2172 crossref_primary_10_1186_s12933_025_02700_0 crossref_primary_10_1002_ejhf_2170 crossref_primary_10_1016_j_jchf_2023_06_003 crossref_primary_10_1002_ejhf_3024 crossref_primary_10_1016_j_cpcardiol_2022_101382 crossref_primary_10_1016_j_diabres_2022_110161 crossref_primary_10_1002_ehf2_15136 crossref_primary_10_1016_j_jacc_2021_12_012 crossref_primary_10_1016_j_amjcard_2021_04_017 crossref_primary_10_1016_j_semarthrit_2022_152058 crossref_primary_10_1016_j_cardfail_2021_04_023 crossref_primary_10_3390_jcdd9070225 crossref_primary_10_3390_jcm10194409 crossref_primary_10_1038_s41569_023_00887_x crossref_primary_10_1016_j_rec_2022_04_019 crossref_primary_10_1093_ndt_gfae058 crossref_primary_10_1001_jamanetworkopen_2021_42078 crossref_primary_10_1016_j_yjmcc_2022_03_005 crossref_primary_10_1016_j_hlc_2023_11_022 crossref_primary_10_1111_bcpt_13714 crossref_primary_10_1016_j_ejim_2023_10_008 crossref_primary_10_1016_j_disamonth_2023_101634 crossref_primary_10_3390_biom15010039 crossref_primary_10_1016_j_ihj_2023_03_003 crossref_primary_10_1093_eurheartj_ehae566 crossref_primary_10_59556_japi_71_0440 crossref_primary_10_1093_eurheartj_ehae561 crossref_primary_10_14797_mdcvj_1120 crossref_primary_10_3389_fendo_2022_850836 crossref_primary_10_1007_s12325_021_01711_z crossref_primary_10_3390_jpm14020141 crossref_primary_10_1111_jcpt_13588 crossref_primary_10_1002_ejhf_3256 crossref_primary_10_1016_j_cardfail_2023_08_011 crossref_primary_10_1186_s12933_025_02777_7 crossref_primary_10_1007_s11883_021_00952_1 crossref_primary_10_1016_j_jacc_2023_07_024 crossref_primary_10_1111_pace_14880 crossref_primary_10_1016_j_ijcard_2021_12_015 crossref_primary_10_1186_s12933_021_01213_w crossref_primary_10_1007_s13300_022_01228_w crossref_primary_10_1016_j_ando_2022_09_023 crossref_primary_10_1002_ehf2_14095 crossref_primary_10_1007_s11886_022_01677_6 crossref_primary_10_1038_s41581_022_00535_6 crossref_primary_10_1016_j_numecd_2025_104033 crossref_primary_10_1007_s13300_022_01204_4 crossref_primary_10_1097_TP_0000000000005503 crossref_primary_10_1016_j_cjca_2023_04_022 crossref_primary_10_1038_s41591_021_01536_x crossref_primary_10_1038_s41574_025_01170_4 crossref_primary_10_1111_dom_14805 crossref_primary_10_1016_j_jchf_2024_01_024 crossref_primary_10_1016_j_jchf_2024_01_025 crossref_primary_10_1007_s11906_023_01240_w crossref_primary_10_1002_ejhf_3240 crossref_primary_10_1007_s11560_023_00685_z crossref_primary_10_1161_HCQ_0000000000000132 crossref_primary_10_1002_ejhf_2399 crossref_primary_10_1016_j_ancard_2021_05_004 crossref_primary_10_1186_s12882_023_03339_3 crossref_primary_10_1002_ejhf_2397 crossref_primary_10_1056_NEJMe2033176 crossref_primary_10_7759_cureus_31777 crossref_primary_10_18087_cardio_2021_12_n1860 crossref_primary_10_1038_s12276_023_01002_3 crossref_primary_10_1016_j_cpcardiol_2023_101817 crossref_primary_10_1186_s13561_023_00466_3 crossref_primary_10_1111_jce_16344 crossref_primary_10_3390_life12081112 crossref_primary_10_1002_phar_2527 crossref_primary_10_1111_bcpt_13739 crossref_primary_10_1007_s00228_021_03261_3 crossref_primary_10_1056_NEJMc2102961 crossref_primary_10_1177_10742484241252474 crossref_primary_10_1080_14728214_2023_2277762 crossref_primary_10_4239_wjd_v16_i6_104706 crossref_primary_10_1007_s12181_021_00446_z crossref_primary_10_34067_KID_0001172021 crossref_primary_10_1038_s41591_022_01971_4 crossref_primary_10_1002_ejhf_2149 crossref_primary_10_1007_s10741_022_10256_4 crossref_primary_10_1093_ejendo_lvad078 crossref_primary_10_1210_clinem_dgaf295 crossref_primary_10_3390_medicina59020388 crossref_primary_10_1080_14656566_2021_2003329 crossref_primary_10_1016_j_advms_2022_01_003 crossref_primary_10_1002_ehf2_14090 crossref_primary_10_1016_j_neurot_2023_11_002 crossref_primary_10_1080_14779072_2023_2273900 crossref_primary_10_1016_j_cardfail_2021_05_012 crossref_primary_10_1038_s41569_021_00605_5 crossref_primary_10_2147_DDDT_S281602 crossref_primary_10_3389_fphar_2024_1372421 crossref_primary_10_3390_jcm13113196 crossref_primary_10_1002_ejhf_2131 crossref_primary_10_1016_j_ejim_2022_06_008 crossref_primary_10_1161_CIRCHEARTFAILURE_120_007767 crossref_primary_10_3389_fendo_2022_900114 crossref_primary_10_1016_j_cardfail_2023_08_003 crossref_primary_10_1186_s12933_023_01896_3 crossref_primary_10_1002_ejhf_2135 crossref_primary_10_1016_j_cardfail_2021_05_020 crossref_primary_10_1002_ejhf_2378 crossref_primary_10_1002_ejhf_3464 crossref_primary_10_1186_s12933_022_01476_x crossref_primary_10_3390_molecules26237213 crossref_primary_10_1002_ejhf_2137 crossref_primary_10_1016_j_cardfail_2021_11_013 crossref_primary_10_1016_j_cardfail_2021_11_010 crossref_primary_10_1016_j_jacadv_2023_100743 crossref_primary_10_1016_j_jss_2024_09_065 crossref_primary_10_3390_jcm14072328 crossref_primary_10_1016_j_jacc_2024_01_040 crossref_primary_10_3389_fendo_2023_1168755 crossref_primary_10_1016_j_cardfail_2025_09_026 crossref_primary_10_2459_JCM_0000000000001598 crossref_primary_10_1016_j_repce_2021_11_017 crossref_primary_10_1016_j_jchf_2023_09_030 crossref_primary_10_2147_DDDT_S372575 crossref_primary_10_1007_s40256_022_00528_7 crossref_primary_10_1161_CIRCULATIONAHA_120_052446 crossref_primary_10_7759_cureus_35030 crossref_primary_10_36660_abchf_20240027i crossref_primary_10_1002_ehf2_13124 crossref_primary_10_1038_s44161_023_00306_x crossref_primary_10_1002_ejhf_3453 crossref_primary_10_7759_cureus_25476 crossref_primary_10_1002_ejhf_3218 crossref_primary_10_1016_j_phrs_2021_106038 crossref_primary_10_3390_healthcare10122356 crossref_primary_10_4330_wjc_v16_i10_550 crossref_primary_10_1001_jamanetworkopen_2023_30754 crossref_primary_10_1186_s12933_022_01481_0 crossref_primary_10_15829_1560_4071_2021_4534 crossref_primary_10_1016_j_molmet_2022_101549 crossref_primary_10_1002_ejhf_3440 crossref_primary_10_3389_fphar_2025_1558367 crossref_primary_10_1016_j_ejim_2022_05_030 crossref_primary_10_1016_j_repc_2021_07_009 crossref_primary_10_1002_ejhf_3444 crossref_primary_10_1016_j_actpha_2023_12_007 crossref_primary_10_1002_ehf2_14224 crossref_primary_10_1016_j_diabres_2021_108648 crossref_primary_10_1002_ejhf_2116 crossref_primary_10_1002_ejhf_2358 crossref_primary_10_1177_19322968221110878 crossref_primary_10_1007_s10741_022_10267_1 crossref_primary_10_3390_ijms25041972 crossref_primary_10_1016_j_ahj_2024_09_001 crossref_primary_10_3389_fcvm_2022_973129 crossref_primary_10_1097_MD_0000000000026431 crossref_primary_10_1097_FJC_0000000000001380 crossref_primary_10_3390_ijms241814243 crossref_primary_10_1016_j_ccl_2022_06_004 crossref_primary_10_1016_j_jchf_2023_08_007 crossref_primary_10_1111_dom_15901 crossref_primary_10_3389_fphar_2023_925375 crossref_primary_10_4103_jicc_jicc_65_24 crossref_primary_10_1002_ejhf_2584 crossref_primary_10_1155_2021_9927533 crossref_primary_10_3390_molecules30153112 crossref_primary_10_1002_ejhf_2108 crossref_primary_10_1016_j_jacc_2023_09_004 crossref_primary_10_1186_s13098_024_01446_1 crossref_primary_10_3390_biomedicines9101356 crossref_primary_10_1093_eurheartj_ehab704 crossref_primary_10_1007_s40265_021_01666_z crossref_primary_10_3389_fphar_2022_877797 crossref_primary_10_1002_dmrr_3755 crossref_primary_10_1007_s00592_021_01757_z crossref_primary_10_9778_cmajo_20210281 crossref_primary_10_1016_j_cardfail_2023_05_015 crossref_primary_10_1016_j_cardfail_2023_05_016 crossref_primary_10_1016_j_bbrc_2025_151338 crossref_primary_10_1093_eurjpc_zwad400 crossref_primary_10_1002_ejhf_2333 crossref_primary_10_1016_S2213_8587_24_00102_5 crossref_primary_10_1002_ejhf_2576 crossref_primary_10_1016_j_cjca_2021_01_017 crossref_primary_10_1002_ehf2_14687 crossref_primary_10_1016_j_phrs_2021_106049 crossref_primary_10_3390_jcm12123925 crossref_primary_10_1111_jep_13885 crossref_primary_10_1002_ejhf_2336 crossref_primary_10_1007_s11883_020_00900_5 crossref_primary_10_1093_eurheartj_ehab709 crossref_primary_10_1016_j_biopha_2024_117453 crossref_primary_10_2215_CJN_0000000000000414 crossref_primary_10_1016_j_ejphar_2023_176179 crossref_primary_10_1016_j_rec_2025_02_007 crossref_primary_10_1016_S2213_8587_22_00308_4 crossref_primary_10_1002_ejhf_2560 crossref_primary_10_1007_s00125_022_05773_8 crossref_primary_10_3389_fcvm_2023_1046194 crossref_primary_10_3390_jcm12062410 crossref_primary_10_1016_j_rec_2025_02_006 crossref_primary_10_1016_j_kint_2022_06_013 crossref_primary_10_1111_dom_14875 crossref_primary_10_1002_ejhf_3416 crossref_primary_10_1007_s11428_023_01047_y crossref_primary_10_1016_j_ahj_2022_05_016 crossref_primary_10_1016_j_jacadv_2024_101024 crossref_primary_10_3389_fcvm_2024_1379765 crossref_primary_10_3390_life12101663 crossref_primary_10_1136_openhrt_2021_001585 crossref_primary_10_1016_j_jchf_2021_06_011 crossref_primary_10_1016_j_ahj_2022_05_010 crossref_primary_10_3390_hearts4010003 crossref_primary_10_1161_JAHA_122_028820 crossref_primary_10_1007_s11936_021_00905_6 crossref_primary_10_3390_ijms22189852 crossref_primary_10_3390_ph18050735 crossref_primary_10_1161_JAHA_123_033236 crossref_primary_10_1016_j_intimp_2025_114631 crossref_primary_10_1186_s12933_021_01266_x crossref_primary_10_1016_j_ahj_2025_01_020 crossref_primary_10_1111_dom_15734 crossref_primary_10_1002_ehf2_14024 crossref_primary_10_1016_j_ejmech_2025_117977 crossref_primary_10_1002_ejhf_3646 crossref_primary_10_1007_s40266_022_00920_7 crossref_primary_10_1056_NEJMoa2107038 crossref_primary_10_3389_fcvm_2022_902923 crossref_primary_10_3390_jcm13154555 crossref_primary_10_3390_life15071022 crossref_primary_10_1007_s40620_022_01336_7 crossref_primary_10_1016_j_cpcardiol_2023_101897 crossref_primary_10_1097_CP9_0000000000000073 crossref_primary_10_1002_ejhf_2542 crossref_primary_10_1093_eurheartj_ehae190 crossref_primary_10_1016_j_cardfail_2023_12_018 crossref_primary_10_1002_ehf2_13148 crossref_primary_10_1007_s11560_024_00821_3 crossref_primary_10_1016_j_jacc_2021_11_027 crossref_primary_10_1016_j_cardfail_2023_06_024 crossref_primary_10_1007_s40256_023_00601_9 crossref_primary_10_1016_j_repc_2024_04_012 crossref_primary_10_1002_ehf2_13380 crossref_primary_10_1038_s41581_024_00836_y crossref_primary_10_1097_MS9_0000000000002903 crossref_primary_10_3389_fvets_2025_1480977 crossref_primary_10_7759_cureus_82458 crossref_primary_10_1016_j_ccl_2025_03_001 crossref_primary_10_1093_cvr_cvae047 crossref_primary_10_1093_eurheartj_ehae179 crossref_primary_10_1016_S2213_8587_23_00009_8 crossref_primary_10_1093_eurheartj_ehae176 crossref_primary_10_3390_cells10102699 crossref_primary_10_1136_openhrt_2024_003078 crossref_primary_10_37349_eemd_2025_101435 crossref_primary_10_1016_j_amjms_2024_06_002 crossref_primary_10_1016_j_kint_2022_06_008 crossref_primary_10_1002_ehf2_14248 crossref_primary_10_1002_ejhf_2773 crossref_primary_10_1016_j_jacc_2024_01_029 crossref_primary_10_1093_ehjcvp_pvac001 crossref_primary_10_1002_ehf2_14005 crossref_primary_10_1002_ejhf_2778 crossref_primary_10_1007_s40261_023_01253_y crossref_primary_10_1016_j_jacc_2024_01_027 crossref_primary_10_1002_ejhf_2777 crossref_primary_10_1016_j_jacc_2021_05_027 crossref_primary_10_1097_MNH_0000000000000778 crossref_primary_10_1002_ejhf_3626 crossref_primary_10_1007_s42399_022_01347_2 crossref_primary_10_1186_s12933_021_01362_y crossref_primary_10_1016_j_cardfail_2021_07_011 crossref_primary_10_1016_j_metabol_2024_155931 crossref_primary_10_1016_j_diabres_2022_109871 crossref_primary_10_1016_j_ebiom_2022_104215 crossref_primary_10_1093_ajhp_zxaf025 crossref_primary_10_1097_MNH_0000000000000929 crossref_primary_10_1007_s10557_021_07203_0 crossref_primary_10_1111_jgs_17585 crossref_primary_10_1007_s13300_022_01278_0 crossref_primary_10_1016_j_jchf_2024_05_011 crossref_primary_10_1016_j_dsx_2022_102661 crossref_primary_10_3389_fcvm_2022_942125 crossref_primary_10_1093_ehjopen_oeaf056 crossref_primary_10_1186_s12933_023_02035_8 crossref_primary_10_1210_clinem_dgab274 crossref_primary_10_3389_fcvm_2022_875327 crossref_primary_10_1007_s10557_021_07291_y crossref_primary_10_1080_14779072_2023_2215985 crossref_primary_10_1111_dom_14675 crossref_primary_10_1007_s10741_021_10211_9 crossref_primary_10_3390_biomedicines11030876 crossref_primary_10_1002_ehf2_13760 crossref_primary_10_1097_CRD_0000000000000554 crossref_primary_10_3389_fphar_2024_1349069 crossref_primary_10_1007_s11883_024_01259_7 crossref_primary_10_1093_eurheartj_ehab887 crossref_primary_10_1007_s40119_024_00367_4 crossref_primary_10_1016_j_jacc_2023_12_024 crossref_primary_10_3390_biomedicines10123294 crossref_primary_10_3389_fcvm_2023_1273781 crossref_primary_10_1093_ehjcvp_pvab056 crossref_primary_10_15420_cfr_2024_37 crossref_primary_10_1007_s00398_024_00642_5 crossref_primary_10_1080_14656566_2025_2464905 crossref_primary_10_1080_14656566_2022_2113385 crossref_primary_10_1007_s10557_021_07249_0 crossref_primary_10_1186_s12933_024_02328_6 crossref_primary_10_1161_JAHA_120_019918 crossref_primary_10_1002_ejhf_2633 crossref_primary_10_1002_ejhf_2874 crossref_primary_10_1016_j_amjcard_2021_07_035 crossref_primary_10_1093_eurheartj_ehad617 crossref_primary_10_1016_j_jchf_2023_11_021 crossref_primary_10_1038_s41569_024_00997_0 crossref_primary_10_1016_j_jacc_2021_08_009 crossref_primary_10_1007_s10557_021_07301_z crossref_primary_10_1016_j_jacc_2024_06_002 crossref_primary_10_1016_j_dsx_2021_102282 crossref_primary_10_1161_CIR_0000000000001063 crossref_primary_10_3390_life13020497 crossref_primary_10_1007_s40261_021_01098_3 crossref_primary_10_3390_medicina61020202 crossref_primary_10_3390_biomedicines13030608 crossref_primary_10_1093_ajhp_zxad061 crossref_primary_10_1002_ejhf_2864 crossref_primary_10_1016_j_lfs_2024_122594 crossref_primary_10_2337_dci23_0094 crossref_primary_10_3390_ph14080751 crossref_primary_10_1007_s10741_024_10389_8 crossref_primary_10_1016_j_eprac_2022_08_002 crossref_primary_10_1056_NEJMoa2407107 crossref_primary_10_1136_heartjnl_2021_319605 crossref_primary_10_3390_biomedicines12102314 crossref_primary_10_3390_life15030427 crossref_primary_10_1186_s12872_024_04078_5 crossref_primary_10_1016_j_ijcha_2024_101539 crossref_primary_10_1161_CIRCULATIONAHA_121_052792 crossref_primary_10_1001_jamanetworkopen_2021_35152 crossref_primary_10_1016_j_xkme_2021_04_009 crossref_primary_10_1080_14656566_2022_2047647 crossref_primary_10_1097_MS9_0000000000003357 crossref_primary_10_1097_MS9_0000000000003592 crossref_primary_10_3390_ijms22115863 crossref_primary_10_1016_j_cardfail_2022_01_016 crossref_primary_10_1007_s40256_021_00484_8 crossref_primary_10_1093_ehjcvp_pvad012 crossref_primary_10_1136_bmj_2023_077025 crossref_primary_10_1111_dom_15320 crossref_primary_10_1007_s12265_022_10302_4 crossref_primary_10_1007_s11886_023_01865_y crossref_primary_10_1016_j_jacc_2021_08_064 crossref_primary_10_1093_eurheartj_suab066 crossref_primary_10_1016_j_jchf_2024_04_003 crossref_primary_10_1161_CIR_0000000000001040 crossref_primary_10_1155_2023_1552826 crossref_primary_10_3389_fcvm_2023_1228789 crossref_primary_10_3390_jcm12010379 crossref_primary_10_15829_1560_4071_2021_4235 crossref_primary_10_1186_s12933_022_01679_2 crossref_primary_10_1093_eurheartj_ehab601 crossref_primary_10_1097_MD_0000000000026561 crossref_primary_10_4103_ijp_ijp_342_21 crossref_primary_10_1007_s13300_022_01289_x crossref_primary_10_3389_fcvm_2021_810791 crossref_primary_10_15829_1560_4071_2021_4699 crossref_primary_10_15829_1728_8800_2025_4466 crossref_primary_10_1007_s11606_024_09073_2 crossref_primary_10_1007_s11886_021_01486_3 crossref_primary_10_1016_j_cpcardiol_2024_102779 crossref_primary_10_1097_CP9_0000000000000112 crossref_primary_10_1210_clinem_dgac558 crossref_primary_10_1016_j_ejphar_2021_174378 crossref_primary_10_1097_FJC_0000000000001176 crossref_primary_10_2174_1381612829666230217143324 crossref_primary_10_3390_ijms231911987 crossref_primary_10_12968_hmed_2024_0546 crossref_primary_10_1016_j_jchf_2024_04_018 crossref_primary_10_1097_CRD_0000000000000760 crossref_primary_10_1093_ehjcvp_pvad035 crossref_primary_10_1093_eurjpc_zwac171 crossref_primary_10_1177_20420188211044945 crossref_primary_10_3390_jcm11175199 crossref_primary_10_1093_eurheartj_ehab876 crossref_primary_10_1016_j_jchf_2021_08_006 crossref_primary_10_1111_eci_13970 crossref_primary_10_1016_j_ccl_2023_06_007 crossref_primary_10_1161_CIRCHEARTFAILURE_121_009462 crossref_primary_10_3390_pharmacy10060166 crossref_primary_10_1136_heartjnl_2020_318242 crossref_primary_10_1093_postmj_qgae148 crossref_primary_10_1038_s41401_023_01068_9 crossref_primary_10_1177_1358863X221143811 crossref_primary_10_1002_ehf2_14638 crossref_primary_10_1186_s12933_023_01911_7 crossref_primary_10_1016_j_amjmed_2021_04_024 crossref_primary_10_1002_ehf2_13785 crossref_primary_10_1002_ehf2_14633 crossref_primary_10_2337_dc21_2166 crossref_primary_10_3390_jcm14082833 crossref_primary_10_1097_MNH_0000000000000703 crossref_primary_10_1055_a_2481_2004 crossref_primary_10_3390_jcm13123562 crossref_primary_10_1007_s42000_025_00702_x crossref_primary_10_1053_j_jvca_2025_06_015 crossref_primary_10_1097_CRD_0000000000000532 crossref_primary_10_15829_1560_4071_2024_5602 crossref_primary_10_1002_ejhf_2825 crossref_primary_10_1007_s10741_021_10083_z crossref_primary_10_3390_healthcare12070753 crossref_primary_10_1016_j_jchf_2022_01_019 crossref_primary_10_1016_j_ejps_2023_106644 crossref_primary_10_1016_j_jchf_2024_05_024 crossref_primary_10_1016_j_ejim_2024_05_009 crossref_primary_10_1186_s12933_022_01646_x crossref_primary_10_3390_jcm10163682 crossref_primary_10_3389_fendo_2022_1078686 crossref_primary_10_1038_s41591_022_01703_8 crossref_primary_10_1136_heartjnl_2021_319643 crossref_primary_10_3389_fendo_2021_743807 crossref_primary_10_1002_ehf2_14647 crossref_primary_10_5694_mja2_51656 crossref_primary_10_1002_ehf2_13553 crossref_primary_10_1016_j_ijcard_2022_11_052 crossref_primary_10_1002_ehf2_13313 crossref_primary_10_7326_M22_2904 crossref_primary_10_3390_ijms23073587 crossref_primary_10_1097_MNH_0000000000000935 crossref_primary_10_1016_j_cardfail_2022_02_011 crossref_primary_10_1161_JAHA_122_029058 crossref_primary_10_1016_j_jacc_2022_04_011 crossref_primary_10_1161_JAHA_123_031805 crossref_primary_10_1186_s12933_022_01575_9 crossref_primary_10_1111_dme_14780 crossref_primary_10_1007_s15027_021_3544_y crossref_primary_10_1186_s12913_024_11520_z crossref_primary_10_1038_s41569_022_00824_4 crossref_primary_10_1016_j_mcna_2025_04_010 crossref_primary_10_1111_jdi_13859 crossref_primary_10_1186_s12933_024_02181_7 crossref_primary_10_1016_j_jacc_2024_05_057 crossref_primary_10_3390_biomedicines11082236 crossref_primary_10_1111_dom_15122 crossref_primary_10_1111_dom_15364 crossref_primary_10_1016_j_pcad_2025_04_004 crossref_primary_10_1093_ehjcvp_pvad088 crossref_primary_10_7759_cureus_45525 crossref_primary_10_1016_j_amjcard_2021_09_029 crossref_primary_10_3390_ijms22020660 crossref_primary_10_5527_wjn_v12_i5_182 crossref_primary_10_1159_000519905 crossref_primary_10_3390_ijms252312941 crossref_primary_10_1016_j_pharmthera_2022_108185 crossref_primary_10_2337_dc22_0772 crossref_primary_10_1161_CIRCULATIONAHA_124_069695 crossref_primary_10_3389_fendo_2022_851035 crossref_primary_10_1016_j_jcte_2024_100335 crossref_primary_10_1016_j_amjmed_2023_04_019 crossref_primary_10_1016_j_ijcrp_2024_200278 crossref_primary_10_1161_CIRCULATIONAHA_122_062021 crossref_primary_10_3390_ijms222312677 crossref_primary_10_3389_fphar_2025_1523727 crossref_primary_10_3389_fcvm_2021_720690 crossref_primary_10_1016_j_jacadv_2025_101615 crossref_primary_10_1186_s12933_022_01455_2 crossref_primary_10_1007_s00059_024_05286_7 crossref_primary_10_1007_s40265_023_01887_4 crossref_primary_10_1016_j_cell_2024_06_029 crossref_primary_10_1016_j_clinsp_2023_100263 crossref_primary_10_1016_j_amjmed_2023_04_035 crossref_primary_10_1038_s41574_022_00776_2 crossref_primary_10_1177_10600280251336751 crossref_primary_10_1016_j_cpcardiol_2024_102388 crossref_primary_10_23736_S2724_5683_24_06500_1 crossref_primary_10_3389_fendo_2024_1451100 crossref_primary_10_1002_ehf2_13905 crossref_primary_10_7759_cureus_21768 crossref_primary_10_1016_j_revmed_2021_10_001 crossref_primary_10_1177_10600280231211179 crossref_primary_10_1016_j_amjcard_2022_03_010 crossref_primary_10_1161_JAHA_123_034053 crossref_primary_10_1007_s00108_021_01083_0 crossref_primary_10_1136_heartjnl_2024_324847 crossref_primary_10_1038_s41591_023_02567_2 crossref_primary_10_1186_s12913_023_10376_z crossref_primary_10_3390_biom15020213 crossref_primary_10_1016_j_amjmed_2022_10_021 crossref_primary_10_1186_s12872_023_03403_8 crossref_primary_10_1002_ehf2_15088 crossref_primary_10_1186_s12933_021_01295_6 crossref_primary_10_33590_emj_22_00026 crossref_primary_10_3390_jcm11010137 crossref_primary_10_2147_DDDT_S418321 crossref_primary_10_1016_j_intimp_2022_109080 crossref_primary_10_1093_ehjqcco_qcae081 crossref_primary_10_3390_ijms24032856 crossref_primary_10_1016_j_diabres_2025_112278 crossref_primary_10_1016_j_tips_2024_06_002 crossref_primary_10_1080_21548331_2022_2082776 crossref_primary_10_1053_j_jvca_2025_05_010 crossref_primary_10_1002_ehf2_13910 crossref_primary_10_3389_fendo_2025_1506652 crossref_primary_10_3389_fphar_2024_1373314 crossref_primary_10_1016_j_jacc_2023_03_393 crossref_primary_10_1016_j_repc_2022_06_013 crossref_primary_10_1177_20420188211042145 crossref_primary_10_1007_s10741_021_10170_1 crossref_primary_10_1016_j_mcna_2025_03_001 crossref_primary_10_1093_eurheartj_ehad639 crossref_primary_10_1136_bmjdrc_2021_002300 crossref_primary_10_3390_jcm12082824 crossref_primary_10_1016_j_accpm_2025_101481 crossref_primary_10_1007_s10741_025_10497_z crossref_primary_10_1016_j_cardfail_2021_08_013 crossref_primary_10_1016_j_ejphar_2022_175357 crossref_primary_10_1016_j_jacc_2024_05_014 crossref_primary_10_1016_j_ejphar_2022_175354 crossref_primary_10_1016_j_ejphar_2024_176858 crossref_primary_10_1093_ageing_afad254 crossref_primary_10_4330_wjc_v14_i11_599 crossref_primary_10_1080_17425255_2022_2105693 crossref_primary_10_1186_s13075_023_03243_z crossref_primary_10_3389_fendo_2023_1216160 crossref_primary_10_1111_dom_16011 crossref_primary_10_1016_j_jjcc_2023_06_008 crossref_primary_10_1016_j_diabres_2025_112219 crossref_primary_10_1016_j_pharmr_2025_100082 crossref_primary_10_1016_S0140_6736_21_00536_5 crossref_primary_10_1016_j_cjca_2020_12_028 crossref_primary_10_1093_eurheartj_ehac530 crossref_primary_10_1080_14779072_2023_2159810 crossref_primary_10_1002_ejhf_3087 crossref_primary_10_1080_17512433_2023_2173574 crossref_primary_10_36290_kar_2022_029 crossref_primary_10_5937_scriptamed56_56443 crossref_primary_10_1007_s12471_021_01579_2 crossref_primary_10_1007_s10557_021_07243_6 crossref_primary_10_1111_dom_15171 crossref_primary_10_3390_medicina61020211 crossref_primary_10_1007_s10741_021_10096_8 crossref_primary_10_1002_jac5_1871 crossref_primary_10_1007_s10557_022_07371_7 crossref_primary_10_1016_j_rce_2025_502300 crossref_primary_10_3389_fcvm_2022_857952 crossref_primary_10_1093_eurheartj_ehab234 crossref_primary_10_1007_s00392_021_01913_z crossref_primary_10_1016_j_ijcard_2021_05_050 crossref_primary_10_5334_gh_1258 crossref_primary_10_1080_07853890_2021_1968028 crossref_primary_10_3390_ijms25031574 crossref_primary_10_1093_ajh_hpad073 crossref_primary_10_1016_j_jacc_2024_03_429 crossref_primary_10_3390_jcm11071904 crossref_primary_10_1007_s10741_025_10518_x crossref_primary_10_1016_j_cmet_2021_10_011 crossref_primary_10_1016_j_amjcard_2021_09_002 crossref_primary_10_1016_j_jacc_2021_09_015 crossref_primary_10_1111_dom_14296 crossref_primary_10_1038_s41598_023_48716_y crossref_primary_10_1016_j_dsx_2021_01_006 crossref_primary_10_3390_jcm10194325 crossref_primary_10_1136_heartjnl_2020_318658 crossref_primary_10_34067_KID_0000000000000250 crossref_primary_10_1007_s10741_022_10238_6 crossref_primary_10_1016_j_hfc_2021_05_003 crossref_primary_10_7717_peerj_15647 crossref_primary_10_1016_j_hfc_2021_05_002 crossref_primary_10_1007_s11886_023_01961_z crossref_primary_10_1016_j_jacc_2024_06_036 crossref_primary_10_1001_jamanetworkopen_2024_46684 crossref_primary_10_1038_s41598_021_91546_z crossref_primary_10_1080_07391102_2022_2130983 crossref_primary_10_1186_s12933_023_02042_9 crossref_primary_10_1016_j_ccl_2024_12_002 crossref_primary_10_1007_s40265_021_01538_6 crossref_primary_10_3390_ijms25052484 crossref_primary_10_1080_17512433_2024_2390921 crossref_primary_10_1007_s13340_021_00515_4 crossref_primary_10_1007_s13300_025_01696_w crossref_primary_10_3389_fcvm_2021_679124 crossref_primary_10_1007_s11886_021_01591_3 crossref_primary_10_1111_dom_15394 crossref_primary_10_7326_AITC202312190 crossref_primary_10_3390_biomedicines11020279 crossref_primary_10_1016_j_ejim_2021_05_017 crossref_primary_10_2337_dc21_1722 crossref_primary_10_1111_nyas_15259 crossref_primary_10_3389_fphar_2022_986186 crossref_primary_10_1080_21548331_2025_2463879 crossref_primary_10_1007_s10557_021_07309_5 crossref_primary_10_1097_CCM_0000000000005869 crossref_primary_10_1002_ejhf_3174 crossref_primary_10_1111_imj_15393 crossref_primary_10_1016_j_lpm_2023_104219 crossref_primary_10_1093_ehjqcco_qcab088 crossref_primary_10_1016_j_jacadv_2023_100818 crossref_primary_10_3390_jcm13237093 crossref_primary_10_1038_s41598_024_51744_x crossref_primary_10_1186_s12933_024_02136_y crossref_primary_10_2337_dc24_0946 crossref_primary_10_3390_diagnostics15050540 crossref_primary_10_2174_1381612829666230703161058 crossref_primary_10_1093_eurheartj_ehad389 crossref_primary_10_1038_s44161_025_00657_7 crossref_primary_10_1093_ehjqcco_qcab072 crossref_primary_10_1002_ejhf_2070 crossref_primary_10_1097_FJC_0000000000001659 crossref_primary_10_1002_ejhf_2075 crossref_primary_10_1016_j_hfc_2022_03_010 crossref_primary_10_1002_ehf2_15036 crossref_primary_10_1016_j_hfc_2024_06_004 crossref_primary_10_2337_dc23_S010 crossref_primary_10_1111_eci_70080 crossref_primary_10_7759_cureus_86368 crossref_primary_10_1371_journal_pone_0261986 crossref_primary_10_1016_j_jacc_2024_09_004 crossref_primary_10_1161_JAHA_122_028732 crossref_primary_10_1080_14656566_2022_2143263 crossref_primary_10_1007_s10741_021_10186_7 crossref_primary_10_1016_j_microc_2024_110713 crossref_primary_10_1002_ejhf_2065 crossref_primary_10_1016_j_medj_2022_10_001 crossref_primary_10_3390_ijms24119760 crossref_primary_10_1016_j_hfc_2022_03_003 crossref_primary_10_1136_heartjnl_2021_319185 crossref_primary_10_1016_j_hfc_2022_03_008 crossref_primary_10_3390_jcm11113192 crossref_primary_10_1016_j_hfc_2022_03_009 crossref_primary_10_1016_j_hfc_2022_03_006 crossref_primary_10_3390_healthcare13111239 crossref_primary_10_1111_dom_15185 crossref_primary_10_3390_jcdd12030104 crossref_primary_10_1007_s40264_022_01166_3 crossref_primary_10_4239_wjd_v12_i5_541 crossref_primary_10_1002_phar_2839 crossref_primary_10_1080_17512433_2022_2051480 crossref_primary_10_1016_j_ijcard_2024_132304 crossref_primary_10_7759_cureus_37388 crossref_primary_10_1001_jama_2024_27402 crossref_primary_10_1016_j_jchf_2025_03_014 crossref_primary_10_3390_medicina60091542 crossref_primary_10_1016_j_clinthera_2024_06_010 crossref_primary_10_1016_j_ijcard_2022_06_059 crossref_primary_10_2337_dc21_1765 crossref_primary_10_3390_biomedicines10051168 crossref_primary_10_1016_j_cpcardiol_2021_100904 crossref_primary_10_3390_life13040951 crossref_primary_10_1007_s12181_022_00562_4 crossref_primary_10_1177_10742484231162248 crossref_primary_10_1186_s12916_025_04018_w crossref_primary_10_1093_eurheartj_ehad353 crossref_primary_10_1002_ejhf_2286 crossref_primary_10_1007_s40261_023_01283_6 crossref_primary_10_3390_jcdd10110465 crossref_primary_10_1007_s10741_023_10363_w crossref_primary_10_1007_s12181_023_00655_8 crossref_primary_10_1016_j_diabres_2025_112050 crossref_primary_10_3390_jpm11121249 crossref_primary_10_1007_s12265_023_10433_2 crossref_primary_10_1007_s40200_024_01545_w crossref_primary_10_1007_s40256_024_00641_9 crossref_primary_10_1177_20406223221086996 crossref_primary_10_1111_1753_0407_13182 crossref_primary_10_1016_j_ajpc_2025_100928 crossref_primary_10_1016_j_hlc_2023_08_011 crossref_primary_10_3389_fendo_2021_664533 crossref_primary_10_2337_dc20_3007 crossref_primary_10_1002_ejhf_2279 crossref_primary_10_3389_fendo_2022_968478 crossref_primary_10_3390_antiox13111330 crossref_primary_10_4330_wjc_v13_i9_464 crossref_primary_10_1007_s00508_023_02186_4 crossref_primary_10_1016_j_cardfail_2025_02_014 crossref_primary_10_7326_M21_0651 crossref_primary_10_7326_M21_0893 crossref_primary_10_1002_ehf2_15293 crossref_primary_10_2215_CJN_0000000000000159 crossref_primary_10_1177_87551225241261040 crossref_primary_10_1002_psb_2014 crossref_primary_10_1016_j_jacc_2023_02_022 crossref_primary_10_7759_cureus_29579 crossref_primary_10_1093_eurheartj_ehaf314 crossref_primary_10_1186_s12933_024_02180_8 crossref_primary_10_17352_2455_2976_000188 crossref_primary_10_1016_j_cmet_2024_06_003 crossref_primary_10_1111_dme_14600 crossref_primary_10_3390_ijms23158631 crossref_primary_10_3389_fphar_2022_677589 crossref_primary_10_3390_ph17111419 crossref_primary_10_1002_clc_24104 crossref_primary_10_1016_j_hsr_2023_100130 crossref_primary_10_1016_j_jchf_2024_09_017 crossref_primary_10_1016_j_cpcardiol_2022_101293 crossref_primary_10_1007_s00392_021_01867_2 crossref_primary_10_1016_j_jacc_2024_03_385 crossref_primary_10_3389_fimmu_2022_977413 crossref_primary_10_3390_life12122062 crossref_primary_10_1007_s12265_022_10220_5 crossref_primary_10_1002_ehf2_15286 crossref_primary_10_1111_dom_16077 crossref_primary_10_1097_MS9_0000000000001773 crossref_primary_10_1186_s12933_022_01607_4 crossref_primary_10_1161_CIRCULATIONAHA_122_059725 crossref_primary_10_1016_j_ahj_2024_02_021 crossref_primary_10_1016_j_recesp_2025_02_009 crossref_primary_10_1253_circj_CJ_25_0002 crossref_primary_10_2337_dc23_1129 crossref_primary_10_1007_s00125_022_05787_2 crossref_primary_10_1016_j_recesp_2025_02_011 crossref_primary_10_1080_00325481_2021_2002580 crossref_primary_10_1007_s00059_022_05134_6 crossref_primary_10_1016_j_diabet_2025_101645 crossref_primary_10_1038_s41598_021_89752_w crossref_primary_10_23736_S0026_4806_25_09607_7 crossref_primary_10_70389_PJBS_100009 crossref_primary_10_1002_ejhf_3109 crossref_primary_10_1161_CIRCULATIONAHA_122_060700 crossref_primary_10_1080_14656566_2021_1998458 crossref_primary_10_1097_MEJ_0000000000001151 crossref_primary_10_1111_dom_14715 crossref_primary_10_1111_joim_13620 crossref_primary_10_3389_fendo_2023_1236404 crossref_primary_10_3389_fcvm_2021_691907 crossref_primary_10_1016_j_cpcardiol_2023_101596 crossref_primary_10_1016_j_cpcardiol_2023_101597 crossref_primary_10_3390_biomedicines13010135 crossref_primary_10_1016_j_ccl_2024_02_005 crossref_primary_10_1016_j_ijcard_2022_03_018 crossref_primary_10_2337_dc22_S010 crossref_primary_10_1097_FJC_0000000000001248 crossref_primary_10_4330_wjc_v17_i1_100886 crossref_primary_10_1016_j_cardfail_2024_07_020 crossref_primary_10_1186_s13098_024_01325_9 crossref_primary_10_1002_ejhf_2249 crossref_primary_10_1002_ehf2_13483 crossref_primary_10_3389_fendo_2024_1376446 crossref_primary_10_3390_ijms23147966 crossref_primary_10_1056_NEJMe2113008 crossref_primary_10_1016_j_rec_2024_01_008 crossref_primary_10_1007_s12325_021_01989_z crossref_primary_10_1001_jamanetworkopen_2024_5135 crossref_primary_10_1016_j_rec_2024_01_011 crossref_primary_10_1093_eurheartjsupp_suac106 crossref_primary_10_1161_JAHA_123_032463 crossref_primary_10_1093_cvr_cvad096 crossref_primary_10_3389_fphys_2021_752370 crossref_primary_10_1007_s40261_021_01105_7 crossref_primary_10_1016_j_jcjd_2024_06_003 crossref_primary_10_1016_j_ejim_2021_03_027 crossref_primary_10_1016_j_cardfail_2024_08_045 crossref_primary_10_1016_j_cpcardiol_2025_103081 crossref_primary_10_1080_17446651_2023_2210673 crossref_primary_10_1186_s12933_022_01601_w crossref_primary_10_3389_fcvm_2025_1543153 crossref_primary_10_1210_jendso_bvac191 crossref_primary_10_1093_eurheartj_ehab832 crossref_primary_10_3390_jcm12226956 crossref_primary_10_1016_j_jacadv_2024_101131 crossref_primary_10_1016_j_mehy_2022_110804 crossref_primary_10_1093_eurheartjsupp_suac113 crossref_primary_10_1177_01410768231198442 crossref_primary_10_1007_s10741_021_10111_y crossref_primary_10_1007_s10741_021_10157_y crossref_primary_10_1007_s40256_022_00527_8 crossref_primary_10_1161_JAHA_123_030495 crossref_primary_10_1002_ehf2_15408 crossref_primary_10_1210_clinem_dgaf133 crossref_primary_10_1016_j_amjmed_2023_01_024 crossref_primary_10_1016_j_cardfail_2025_01_008 crossref_primary_10_1007_s11428_023_01144_y crossref_primary_10_1002_ejhf_3558 crossref_primary_10_3389_fphar_2022_919974 crossref_primary_10_1093_eurheartjsupp_suac120 crossref_primary_10_1136_bmjopen_2024_090226 crossref_primary_10_3389_fphar_2022_800490 crossref_primary_10_15829_1560_4071_2021_4436 crossref_primary_10_3389_fendo_2025_1563362 crossref_primary_10_1161_CIRCULATIONAHA_122_062918 crossref_primary_10_1016_j_ccl_2021_04_007 crossref_primary_10_1093_eurheartjsupp_suac124 crossref_primary_10_1186_s12933_021_01430_3 crossref_primary_10_36660_abchf_20220013 crossref_primary_10_1016_j_ccl_2021_04_001 crossref_primary_10_36660_abchf_20220018 crossref_primary_10_1016_S2213_8587_23_00128_6 crossref_primary_10_1002_ehf2_13472 crossref_primary_10_1002_ejhf_2214 crossref_primary_10_3389_fpubh_2024_1412874 crossref_primary_10_1016_j_ejim_2021_03_001 crossref_primary_10_36660_abchf_20220011 crossref_primary_10_1038_s41591_021_01659_1 crossref_primary_10_1097_HJH_0000000000002910 crossref_primary_10_7759_cureus_57380 crossref_primary_10_3389_fcvm_2023_1143658 crossref_primary_10_3390_life13061256 crossref_primary_10_1007_s40266_024_01165_2 crossref_primary_10_7759_cureus_75802 crossref_primary_10_1111_dom_14513 crossref_primary_10_1002_ejhf_2441 crossref_primary_10_3390_jcm11061470 crossref_primary_10_1186_s12933_022_01516_6 crossref_primary_10_1002_bcp_70187 crossref_primary_10_1016_j_jacc_2022_07_021 crossref_primary_10_1002_ejhf_2206 crossref_primary_10_1007_s12020_023_03618_x crossref_primary_10_1186_s12933_021_01254_1 crossref_primary_10_1186_s12933_021_01408_1 crossref_primary_10_54022_shsv6n3_020 crossref_primary_10_1055_a_2546_0353 crossref_primary_10_3389_fcvm_2022_903902 crossref_primary_10_1139_cjpp_2022_0154 crossref_primary_10_61384_r_c_a__v5i3_1365 crossref_primary_10_1136_heartjnl_2024_324160 crossref_primary_10_3390_ijms23073651 crossref_primary_10_1016_j_phrs_2022_106243 crossref_primary_10_1016_j_nefroe_2024_03_011 crossref_primary_10_1161_CIRCHEARTFAILURE_123_011173 crossref_primary_10_1007_s11096_022_01504_6 crossref_primary_10_1016_j_amjcard_2022_08_035 crossref_primary_10_1093_eurheartj_ehad192 crossref_primary_10_1097_CRD_0000000000000484 crossref_primary_10_1210_clinem_dgaf301 crossref_primary_10_1016_j_ijcard_2025_133079 crossref_primary_10_1093_eurheartj_ehad195 crossref_primary_10_1002_ejhf_2433 crossref_primary_10_1002_ejhf_2678 crossref_primary_10_1097_MD_0000000000027802 crossref_primary_10_3390_jcdd10080322 crossref_primary_10_1016_j_jchf_2022_08_009 crossref_primary_10_3389_fcvm_2024_1388337 crossref_primary_10_1038_s41392_024_01951_9 crossref_primary_10_1186_s13643_025_02766_7 crossref_primary_10_1097_HCO_0000000000001108 crossref_primary_10_1016_j_hlpt_2025_101077 crossref_primary_10_3389_fphar_2024_1419729 crossref_primary_10_3390_jcm11175027 crossref_primary_10_1177_17539447241289067 crossref_primary_10_1016_j_cegh_2024_101555 crossref_primary_10_1002_ehf2_14354 crossref_primary_10_1002_ehf2_14355 crossref_primary_10_1016_j_jchf_2023_01_018 crossref_primary_10_1007_s10741_022_10275_1 crossref_primary_10_1002_edm2_303 crossref_primary_10_1007_s11886_022_01694_5 crossref_primary_10_1016_j_cardfail_2022_10_001 crossref_primary_10_1161_CIRCRESAHA_121_318159 crossref_primary_10_2337_dc24_S010 crossref_primary_10_1016_j_cardfail_2022_04_011 crossref_primary_10_1161_CIRCRESAHA_121_318158 crossref_primary_10_1186_s12933_023_01855_y crossref_primary_10_3389_fendo_2025_1605746 crossref_primary_10_3390_ph18060857 crossref_primary_10_1016_j_cjca_2022_04_029 crossref_primary_10_1093_ehjcvp_pvab034 crossref_primary_10_1093_ehjcvp_pvab039 crossref_primary_10_1177_20543581221150556 crossref_primary_10_1007_s11892_021_01442_z crossref_primary_10_3390_jcm13061541 crossref_primary_10_2337_dc24_S009 crossref_primary_10_1002_ejhf_2894 crossref_primary_10_1111_dom_14986 crossref_primary_10_1093_ehjcvp_pvab033 crossref_primary_10_3389_fendo_2023_1111984 crossref_primary_10_1016_j_jchf_2023_01_027 crossref_primary_10_1080_14779072_2022_2057949 crossref_primary_10_3390_jcm11102935 crossref_primary_10_1016_j_jacasi_2022_03_002 crossref_primary_10_1016_j_nephro_2020_12_006 crossref_primary_10_1080_13543784_2023_2263354 crossref_primary_10_1002_ehf2_13646 crossref_primary_10_1093_eurjpc_zwad356 crossref_primary_10_1002_ehf2_14979 crossref_primary_10_1002_ehf2_13406 crossref_primary_10_1007_s13300_021_01083_1 crossref_primary_10_1016_S2213_8587_25_00001_4 crossref_primary_10_1111_dom_14555 crossref_primary_10_1002_ejhf_2766 crossref_primary_10_3390_jcm13051375 crossref_primary_10_1002_ejhf_3618 crossref_primary_10_1093_eurheartj_ehad718 crossref_primary_10_1093_eurheartj_ehab765 crossref_primary_10_1002_ejhf_2508 crossref_primary_10_1002_ejhf_2509 crossref_primary_10_1007_s11606_023_08397_9 crossref_primary_10_1186_s12872_023_03542_y crossref_primary_10_1097_FJC_0000000000001099 crossref_primary_10_1016_j_pcad_2023_10_003 crossref_primary_10_2337_dci22_0034 crossref_primary_10_1002_ejhf_2990 crossref_primary_10_1016_j_nurpra_2024_105088 crossref_primary_10_1016_j_jacasi_2025_01_015 crossref_primary_10_3390_life13112226 crossref_primary_10_1002_ejhf_2754 crossref_primary_10_3390_life12111829 crossref_primary_10_1016_j_repc_2023_05_012 crossref_primary_10_1093_eurheartj_ehab798 crossref_primary_10_1016_j_amsu_2021_102796 crossref_primary_10_1371_journal_pone_0295059 crossref_primary_10_1016_j_dsx_2023_102804 crossref_primary_10_1093_eurheartj_ehac649 crossref_primary_10_1161_JAHA_123_031745 crossref_primary_10_3389_fcvm_2023_1235178 crossref_primary_10_2337_dc25_S009 crossref_primary_10_1016_j_jacc_2022_10_028 crossref_primary_10_1161_CIRCRESAHA_121_318186 crossref_primary_10_1097_MD_0000000000027362 crossref_primary_10_1007_s40265_021_01559_1 crossref_primary_10_1080_14779072_2024_2363395 crossref_primary_10_1111_dom_14772 crossref_primary_10_1007_s12471_021_01580_9 crossref_primary_10_1016_S0140_6736_22_02074_8 crossref_primary_10_1016_j_diabet_2023_101419 crossref_primary_10_3389_fcvm_2022_1067806 crossref_primary_10_1016_j_jacc_2023_03_426 crossref_primary_10_1056_NEJMcp2000280 crossref_primary_10_3389_fendo_2024_1499681 crossref_primary_10_3389_fcvm_2022_1039348 crossref_primary_10_1002_ejhf_2503 crossref_primary_10_1007_s40801_021_00277_0 crossref_primary_10_1007_s11428_023_01109_1 crossref_primary_10_3390_ijms26178202 crossref_primary_10_2337_dc25_S010 crossref_primary_10_1177_10892532221100660 crossref_primary_10_3390_biomedicines10102458 crossref_primary_10_1093_eurheartjsupp_suad056 crossref_primary_10_1093_eurheartjsupp_suad055 crossref_primary_10_1007_s15034_021_3702_4 crossref_primary_10_1093_cvr_cvac187 crossref_primary_10_1016_j_amjcard_2022_10_027 crossref_primary_10_1097_MJT_0000000000001452 crossref_primary_10_3390_pharmaceutics14091964 crossref_primary_10_1002_ehf2_14726 crossref_primary_10_1093_eurjpc_zwab189 crossref_primary_10_7326_ANNALS_24_01100 crossref_primary_10_1002_ejhf_2971 crossref_primary_10_1038_s44324_025_00068_z crossref_primary_10_1016_j_jchf_2023_04_015 crossref_primary_10_3389_fphar_2023_1303694 crossref_primary_10_1007_s10741_024_10453_3 crossref_primary_10_1016_j_ejim_2025_01_014 crossref_primary_10_1016_j_jacasi_2022_03_009 crossref_primary_10_1001_jamanetworkopen_2022_43201 crossref_primary_10_1016_j_jacasi_2021_08_003 crossref_primary_10_1016_j_jacc_2023_03_430 crossref_primary_10_1002_ejhf_2738 crossref_primary_10_1093_ckj_sfac146 crossref_primary_10_1161_CIRCULATIONAHA_122_062769 crossref_primary_10_1016_j_cjca_2022_05_011 crossref_primary_10_1161_CIRCULATIONAHA_122_060348 crossref_primary_10_1016_j_acvd_2025_02_012 crossref_primary_10_1016_S0140_6736_22_01429_5 crossref_primary_10_1097_MD_0000000000025121 crossref_primary_10_1016_j_jchf_2023_02_001 crossref_primary_10_1016_j_ijcard_2022_09_009 crossref_primary_10_1093_cvr_cvac133 crossref_primary_10_1016_j_metabol_2021_154918 crossref_primary_10_3389_fphar_2022_901340 crossref_primary_10_1080_03007995_2023_2189857 crossref_primary_10_1097_CP9_0000000000000007 crossref_primary_10_1161_CIRCULATIONAHA_122_062333 crossref_primary_10_1111_dom_15200 crossref_primary_10_1016_j_jjcc_2022_02_008 crossref_primary_10_1053_j_ajkd_2023_09_003 crossref_primary_10_1016_j_jacasi_2022_02_004 crossref_primary_10_1111_dom_14356 crossref_primary_10_1093_ehjcvp_pvae013 crossref_primary_10_1097_MJT_0000000000001882 crossref_primary_10_1002_ejhf_2720 crossref_primary_10_1111_dom_14593 crossref_primary_10_7759_cureus_68560 crossref_primary_10_1007_s13340_025_00800_6 crossref_primary_10_7759_cureus_73906 crossref_primary_10_1007_s11897_022_00583_w crossref_primary_10_1016_j_cardfail_2024_12_015 crossref_primary_10_1161_CIRCHEARTFAILURE_121_009353 crossref_primary_10_1016_j_biopha_2024_116650 crossref_primary_10_1016_j_cardfail_2024_12_016 crossref_primary_10_1111_nep_70030 crossref_primary_10_1016_j_cjco_2025_02_008 crossref_primary_10_1093_cvr_cvab271 crossref_primary_10_1111_eci_13624 crossref_primary_10_1161_JAHA_124_039105 crossref_primary_10_1016_j_jacc_2022_08_005 crossref_primary_10_1186_s12933_023_02023_y crossref_primary_10_1371_journal_pone_0286307 crossref_primary_10_1093_ehjcvp_pvae003 crossref_primary_10_1038_s41569_020_00486_0 crossref_primary_10_1002_ejhf_2711 crossref_primary_10_1002_ehf2_13452 crossref_primary_10_1007_s11428_022_00921_5 crossref_primary_10_1186_s40001_022_00945_z crossref_primary_10_3390_encyclopedia3030083 crossref_primary_10_1016_j_jacc_2022_03_353 crossref_primary_10_1161_JAHA_121_022222 crossref_primary_10_1016_j_jacadv_2024_101451 crossref_primary_10_1681_ASN_0000000000000477 crossref_primary_10_3390_life13041024 crossref_primary_10_1093_cvr_cvac152 crossref_primary_10_1161_CIRCULATIONAHA_121_056824 crossref_primary_10_1210_jendso_bvae229 crossref_primary_10_1016_j_jacc_2022_11_023 crossref_primary_10_3389_fimmu_2023_1167741 crossref_primary_10_1016_j_diabres_2022_109927 crossref_primary_10_1093_eurheartj_ehab519 crossref_primary_10_1111_1753_0407_70044 crossref_primary_10_1016_j_atherosclerosis_2024_117560 crossref_primary_10_1093_ckj_sfab096 crossref_primary_10_2217_fca_2023_0014 crossref_primary_10_3390_jcm10091803 crossref_primary_10_1016_j_diabres_2021_108796 crossref_primary_10_1097_CD9_0000000000000060 crossref_primary_10_1007_s00604_025_07235_5 crossref_primary_10_1016_j_nurpra_2023_104716 crossref_primary_10_1007_s13300_022_01242_y crossref_primary_10_2459_JCM_0000000000001504 crossref_primary_10_1016_j_amjcard_2022_09_019 crossref_primary_10_1016_j_nbd_2024_106598 crossref_primary_10_1016_j_jchf_2023_03_011 crossref_primary_10_3390_endocrines4030045 crossref_primary_10_2217_fca_2023_0016 crossref_primary_10_2337_dci22_0014 crossref_primary_10_1038_s41467_022_33377_8 crossref_primary_10_3389_fcvm_2022_897423 crossref_primary_10_1186_s40635_023_00562_y crossref_primary_10_1016_j_bcp_2022_115349 crossref_primary_10_1007_s10741_023_10338_x crossref_primary_10_1097_MNH_0000000000000811 crossref_primary_10_1111_jebm_12646 crossref_primary_10_1177_10600280231154021 crossref_primary_10_1016_j_ejim_2021_11_008 crossref_primary_10_1016_j_jacc_2021_02_005 crossref_primary_10_3389_fendo_2021_664502 crossref_primary_10_1002_ejhf_2916 crossref_primary_10_1002_ejhf_2915 crossref_primary_10_1093_eurheartj_ehab136 crossref_primary_10_1161_CIRCULATIONAHA_124_069568 crossref_primary_10_4103_jcor_jcor_148_24 crossref_primary_10_3390_jcm13102775 crossref_primary_10_1007_s10741_021_10182_x crossref_primary_10_3389_fimmu_2023_1213473 crossref_primary_10_3390_ijms23137351 crossref_primary_10_1080_14656566_2023_2204188 crossref_primary_10_1002_ehf2_13805 crossref_primary_10_1016_j_jcjd_2021_12_005 crossref_primary_10_15829_1560_4071_2022_4949 crossref_primary_10_1016_j_jdiacomp_2021_108101 crossref_primary_10_17925_HI_2023_17_2_12 crossref_primary_10_3390_biom15030373 crossref_primary_10_1002_ejhf_2920 crossref_primary_10_1007_s00592_024_02289_y crossref_primary_10_3390_jcdd11060171 crossref_primary_10_1186_s12933_021_01272_z crossref_primary_10_1016_j_jchf_2023_05_026 crossref_primary_10_1093_eurheartj_ehab368 crossref_primary_10_1007_s11883_022_01066_y crossref_primary_10_1002_mdc3_13893 crossref_primary_10_1007_s10557_023_07469_6 crossref_primary_10_3390_jcm10163540 crossref_primary_10_3390_ijms25179186 crossref_primary_10_1016_j_lpm_2023_104184 crossref_primary_10_1016_j_lpm_2023_104185 crossref_primary_10_1038_s41401_022_00889_4 crossref_primary_10_1038_s41598_022_11033_x crossref_primary_10_1080_10408363_2021_1993439 crossref_primary_10_1007_s40265_022_01730_2 crossref_primary_10_1016_j_jacc_2025_06_036 crossref_primary_10_1097_XCE_0000000000000284 crossref_primary_10_1016_j_jacc_2021_03_298 crossref_primary_10_1161_JAHA_121_022667 crossref_primary_10_1111_dom_15019 crossref_primary_10_1007_s10557_023_07434_3 crossref_primary_10_3389_fcvm_2021_787810 crossref_primary_10_3389_fphys_2022_1028486 crossref_primary_10_1111_dom_15251 crossref_primary_10_1016_j_jchf_2022_11_026 crossref_primary_10_3390_ijms25126661 crossref_primary_10_3389_fcvm_2023_1125687 crossref_primary_10_1007_s11897_022_00552_3 crossref_primary_10_3390_jcm10194497 crossref_primary_10_2217_fca_2023_0066 crossref_primary_10_1093_cvr_cvab022 crossref_primary_10_1093_eurheartj_ehac483 crossref_primary_10_1161_CIRCULATIONAHA_121_054442 crossref_primary_10_1001_jamanetworkopen_2021_14501 crossref_primary_10_1016_j_metabol_2021_154937 crossref_primary_10_1080_00015385_2023_2250949 crossref_primary_10_1007_s13679_023_00522_3 crossref_primary_10_57264_cer_2023_0190 crossref_primary_10_1016_j_medj_2021_10_004 crossref_primary_10_1016_j_jchf_2021_01_014 crossref_primary_10_1136_bmjdrc_2022_002995 crossref_primary_10_1146_annurev_pharmtox_052120_014725 crossref_primary_10_1002_clc_23849 crossref_primary_10_2217_fca_2020_0210 crossref_primary_10_1007_s00392_024_02396_4 crossref_primary_10_1016_j_intimp_2025_115461 crossref_primary_10_3390_biomedicines12050981 crossref_primary_10_1007_s10741_022_10281_3 crossref_primary_10_7759_cureus_69623 crossref_primary_10_1016_j_ihj_2024_07_005 crossref_primary_10_1186_s12933_024_02325_9 crossref_primary_10_1002_clc_23846 crossref_primary_10_1016_j_ejim_2025_03_002 crossref_primary_10_1002_clc_23845 crossref_primary_10_1007_s11897_022_00576_9 crossref_primary_10_2147_DMSO_S375559 crossref_primary_10_3389_fcvm_2022_1041200 crossref_primary_10_53986_ibjm_2023_0009 crossref_primary_10_1016_j_cardfail_2025_04_008 crossref_primary_10_1097_MD_0000000000030310 crossref_primary_10_1016_j_eprac_2024_02_004 crossref_primary_10_1016_j_rec_2022_02_006 crossref_primary_10_1016_j_hfc_2022_07_001 crossref_primary_10_1007_s11910_025_01425_7 crossref_primary_10_1002_cdt3_59 crossref_primary_10_1111_dom_15047 crossref_primary_10_3390_ijms23042336 crossref_primary_10_1007_s10557_023_07512_6 crossref_primary_10_3390_jcdd10030114 crossref_primary_10_1002_ehf2_13841 crossref_primary_10_1007_s10741_024_10388_9 crossref_primary_10_1093_ehjcvp_pvae093 crossref_primary_10_1097_MS9_0000000000003658 crossref_primary_10_3390_ijms23031678 crossref_primary_10_1093_eurheartj_ehac417 crossref_primary_10_1186_s12913_022_08614_x crossref_primary_10_1093_eurheartj_ehab560 crossref_primary_10_14814_phy2_70217 crossref_primary_10_1186_s12933_021_01390_8 crossref_primary_10_1016_S2213_8587_24_00362_0 crossref_primary_10_33678_cor_2021_103 crossref_primary_10_1111_dom_16147 crossref_primary_10_1002_ehf2_13615 crossref_primary_10_1016_j_jacadv_2024_100989 crossref_primary_10_1038_s43856_025_00951_2 crossref_primary_10_1016_j_ijcrp_2024_200351 crossref_primary_10_1186_s12933_021_01281_y crossref_primary_10_1111_jce_15894 crossref_primary_10_1080_14779072_2022_2039626 crossref_primary_10_3389_fcvm_2022_864366 crossref_primary_10_1016_j_cardfail_2022_09_009 crossref_primary_10_1093_eurheartj_ehac680 crossref_primary_10_1055_a_1971_3381 crossref_primary_10_1016_j_jacc_2023_04_034 crossref_primary_10_1016_S0140_6736_22_02076_1 crossref_primary_10_7759_cureus_19379 crossref_primary_10_1177_10600280231189508 crossref_primary_10_1146_annurev_med_042220_022745 crossref_primary_10_3390_biomedicines12071456 crossref_primary_10_1016_j_jchf_2022_10_013 crossref_primary_10_7326_M21_4284 crossref_primary_10_17925_HI_2021_15_1_42 crossref_primary_10_1080_17512433_2023_2247977 crossref_primary_10_1186_s12933_020_01209_y crossref_primary_10_1080_14796678_2025_2503666 crossref_primary_10_1016_j_amjcard_2025_07_005 crossref_primary_10_3390_pharmaceutics14081730 crossref_primary_10_1080_00325481_2025_2503696 crossref_primary_10_1016_S2213_8587_21_00082_6 crossref_primary_10_1093_eurheartj_ehad522 crossref_primary_10_1016_j_shj_2022_100082 crossref_primary_10_1159_000528505 crossref_primary_10_1080_14740338_2021_1898585 crossref_primary_10_7759_cureus_88561 |
| Cites_doi | 10.1007/s10985-019-09462-4 10.1016/S0735-1097(00)00531-3 10.1016/j.jacbts.2018.01.010 10.1056/NEJMoa1007964 10.1056/NEJMoa1812389 10.2337/dc18-1959 10.1016/j.jacc.2020.07.051 10.1111/dom.14127 10.2337/dc14-2806 10.1056/NEJMoa1911303 10.1002/sim.4780131709 10.1001/jama.295.2.180 10.1016/j.cmet.2019.08.015 10.1161/CIRCULATIONAHA.119.041181 10.1016/S0140-6736(18)32590-X 10.2337/dc19-1410 10.1056/NEJMoa2004967 10.2337/dc18-0342 10.1161/CIRCULATIONAHA.114.014796 10.1002/ejhf.1713 10.1210/clinem/dgz258 10.2337/dc14-1850 10.2337/dci19-0074 10.1056/NEJMoa1504720 10.1161/CIRCULATIONAHA.119.040130 10.1016/j.jacc.2018.08.2202 10.1038/s41569-020-00439-7 10.1161/CIRCHEARTFAILURE.119.006720 10.1056/NEJMoa1708337 10.1016/j.bbrc.2020.01.015 10.1161/CIRCULATIONAHA.119.042375 10.1001/jama.2010.1322 10.1080/01621459.1989.10478874 10.1016/j.jacc.2020.05.041 10.1093/ndt/gfz294 10.1001/jama.297.11.1197 10.2337/dc18-0343 10.1056/NEJMoa1307684 10.1056/NEJMoa2024816 10.1161/JAHA.120.018274 10.1016/j.jacc.2015.11.027 10.1016/j.cmet.2019.10.008 10.1139/cjpp-2018-0359 10.1056/NEJMoa2022190 10.1016/j.cmet.2018.11.010 10.1056/NEJMoa1611925 10.1161/CIRCULATIONAHA.114.010389 10.1001/jamacardio.2016.3030 10.1016/S2213-8587(15)00044-3 10.1056/NEJMoa1811744 |
| ContentType | Journal Article |
| Contributor | Lamblin, Nicolas Marcus, Jill Francis, Gary S French, William J Mathews, Robin Schou, Morten Middleton, John P Ezekowitz, Justin Celutkiene, Jelena Brown, Linley Barbarash, Olga Ponikowski, Piotr Sposato, Luciano A Tsao, Lana El Shahawy, Mahfouz Weber, Thomas J Povsic, Thomas J McGarrah, Robert W Pitt, Bertram Ben-Gal, Tuvia Verma, Subodh Crespo-Leiro, Maria Generosa Young, James B Merkely, Béla Peter Foucauld, Jean Wilcox, Christopher Erglis, Andrejs Lewis, James Perna, Eduardo Roque Greenberg, Barry Shih, Weichung Joe Mehta, Rajendra H Murin, Jan Lewis, Julia B Mann, Johannes F E Schmalfuss, Carsten Lakey, Wanda C Dungen, Hans-Dirk Kong, David F Hayden, Nikieia Voors, Adriaan Green, Jennifer B Fonseca, Cândida Jones, W Schuyler Jordan, J Dedrick Leeper, Nicholas Wang, Z Sophie Stournaras, Dimitrios Cannon, Christopher P Pun, Patrick H Nicolau, José Carlos Ryu, Kyu-Hyung Mentz, Robert Corbalan Herreros, Ramon Luis Janssens, Stefan Frigerio, Maria Dan, Gheorghe Andrei Leiter, Lawrence A Muller, Christian Eugen Lund, Lars H Yilmaz, Mehmet Birhan |
| Contributor_xml | – sequence: 1 givenname: Deepak L surname: Bhatt fullname: Bhatt, Deepak L – sequence: 2 givenname: Christopher P surname: Cannon fullname: Cannon, Christopher P – sequence: 3 givenname: Lawrence A surname: Leiter fullname: Leiter, Lawrence A – sequence: 4 givenname: Julia B surname: Lewis fullname: Lewis, Julia B – sequence: 5 givenname: Darren K surname: McGuire fullname: McGuire, Darren K – sequence: 6 givenname: Bertram surname: Pitt fullname: Pitt, Bertram – sequence: 7 givenname: Matthew C surname: Riddle fullname: Riddle, Matthew C – sequence: 8 givenname: Gabriel surname: Steg fullname: Steg, Gabriel – sequence: 9 givenname: Hertzel C surname: Gerstein fullname: Gerstein, Hertzel C – sequence: 10 givenname: Gary S surname: Francis fullname: Francis, Gary S – sequence: 11 givenname: John E surname: Gerich fullname: Gerich, John E – sequence: 12 givenname: Johannes F E surname: Mann fullname: Mann, Johannes F E – sequence: 13 givenname: Weichung Joe surname: Shih fullname: Shih, Weichung Joe – sequence: 14 givenname: James B surname: Young fullname: Young, James B – sequence: 15 givenname: Michel surname: Komajda fullname: Komajda, Michel – sequence: 16 givenname: Lars H surname: Lund fullname: Lund, Lars H – sequence: 17 givenname: Marco surname: Metra fullname: Metra, Marco – sequence: 18 givenname: Piotr surname: Ponikowski fullname: Ponikowski, Piotr – sequence: 19 givenname: Jeffrey M surname: Testani fullname: Testani, Jeffrey M – sequence: 20 givenname: Adriaan surname: Voors fullname: Voors, Adriaan – sequence: 21 givenname: Christopher surname: Wilcox fullname: Wilcox, Christopher – sequence: 22 givenname: Renato D surname: Lopes fullname: Lopes, Renato D – sequence: 23 givenname: Jennifer B surname: Green fullname: Green, Jennifer B – sequence: 24 givenname: Karen P surname: Alexander fullname: Alexander, Karen P – sequence: 25 givenname: Bryan C surname: Batch fullname: Batch, Bryan C – sequence: 26 givenname: W Schuyler surname: Jones fullname: Jones, W Schuyler – sequence: 27 givenname: J Dedrick surname: Jordan fullname: Jordan, J Dedrick – sequence: 28 givenname: Bradley J surname: Kolls fullname: Kolls, Bradley J – sequence: 29 givenname: David F surname: Kong fullname: Kong, David F – sequence: 30 givenname: Wanda C surname: Lakey fullname: Lakey, Wanda C – sequence: 31 givenname: Richard H surname: Lee fullname: Lee, Richard H – sequence: 32 givenname: Robin surname: Mathews fullname: Mathews, Robin – sequence: 33 givenname: Robert W surname: McGarrah fullname: McGarrah, Robert W – sequence: 34 givenname: Rajendra H surname: Mehta fullname: Mehta, Rajendra H – sequence: 35 givenname: Chiara surname: Melloni fullname: Melloni, Chiara – sequence: 36 givenname: John P surname: Middleton fullname: Middleton, John P – sequence: 37 givenname: Thomas J surname: Povsic fullname: Povsic, Thomas J – sequence: 38 givenname: Patrick H surname: Pun fullname: Pun, Patrick H – sequence: 39 givenname: Julia J surname: Scialla fullname: Scialla, Julia J – sequence: 40 givenname: Shreyansh surname: Shah fullname: Shah, Shreyansh – sequence: 41 givenname: Luciano A surname: Sposato fullname: Sposato, Luciano A – sequence: 42 givenname: Thomas J surname: Weber fullname: Weber, Thomas J – sequence: 43 givenname: Casey surname: Norris fullname: Norris, Casey – sequence: 44 givenname: Jill surname: Marcus fullname: Marcus, Jill – sequence: 45 givenname: Nikieia surname: Hayden fullname: Hayden, Nikieia – sequence: 46 givenname: Dimitrios surname: Stournaras fullname: Stournaras, Dimitrios – sequence: 47 givenname: Z Sophie surname: Wang fullname: Wang, Z Sophie – sequence: 48 givenname: Linley surname: Brown fullname: Brown, Linley – sequence: 49 givenname: Dominique surname: Larrey fullname: Larrey, Dominique – sequence: 50 givenname: James surname: Lewis fullname: Lewis, James – sequence: 51 givenname: Joshua surname: Beckman fullname: Beckman, Joshua – sequence: 52 givenname: Marc surname: Bonaca fullname: Bonaca, Marc – sequence: 53 givenname: Nicholas surname: Leeper fullname: Leeper, Nicholas – sequence: 54 givenname: Phillip surname: Banks fullname: Banks, Phillip – sequence: 55 givenname: Eshetu surname: Tesfaye fullname: Tesfaye, Eshetu – sequence: 56 givenname: Kenneth surname: Kassler-Taub fullname: Kassler-Taub, Kenneth – sequence: 57 givenname: Chris surname: Warner fullname: Warner, Chris – sequence: 58 givenname: Mark surname: O'Neill fullname: O'Neill, Mark – sequence: 59 givenname: Rosemary Molinari surname: Covance fullname: Covance, Rosemary Molinari – sequence: 60 givenname: Robert surname: Mentz fullname: Mentz, Robert – sequence: 61 givenname: Frank surname: Peacock fullname: Peacock, Frank – sequence: 62 givenname: Barry surname: Greenberg fullname: Greenberg, Barry – sequence: 63 givenname: Subodh surname: Verma fullname: Verma, Subodh – sequence: 64 givenname: Justin surname: Ezekowitz fullname: Ezekowitz, Justin – sequence: 65 givenname: Stefan surname: Janssens fullname: Janssens, Stefan – sequence: 66 givenname: Jeroen surname: Schaap fullname: Schaap, Jeroen – sequence: 67 givenname: Andrew Lawrence surname: Clark fullname: Clark, Andrew Lawrence – sequence: 68 givenname: Morten surname: Schou fullname: Schou, Morten – sequence: 69 givenname: Veli-Pekka surname: Harjola fullname: Harjola, Veli-Pekka – sequence: 70 givenname: Andrejs surname: Erglis fullname: Erglis, Andrejs – sequence: 71 givenname: Jelena surname: Celutkiene fullname: Celutkiene, Jelena – sequence: 72 givenname: Jindrich surname: Spinar fullname: Spinar, Jindrich – sequence: 73 givenname: Jan surname: Murin fullname: Murin, Jan – sequence: 74 givenname: Béla Peter surname: Merkely fullname: Merkely, Béla Peter – sequence: 75 givenname: Jadwiga Maria surname: Nessler fullname: Nessler, Jadwiga Maria – sequence: 76 givenname: Hans-Dirk surname: Dungen fullname: Dungen, Hans-Dirk – sequence: 77 givenname: Kurt surname: Huber fullname: Huber, Kurt – sequence: 78 givenname: Christian Eugen surname: Muller fullname: Muller, Christian Eugen – sequence: 79 givenname: Nicolas surname: Lamblin fullname: Lamblin, Nicolas – sequence: 80 givenname: Piergiuseppe surname: Agostoni fullname: Agostoni, Piergiuseppe – sequence: 81 givenname: Maria surname: Frigerio fullname: Frigerio, Maria – sequence: 82 givenname: John surname: Parissis fullname: Parissis, John – sequence: 83 givenname: Gheorghe Andrei surname: Dan fullname: Dan, Gheorghe Andrei – sequence: 84 givenname: Maria Generosa surname: Crespo-Leiro fullname: Crespo-Leiro, Maria Generosa – sequence: 85 givenname: Tuvia surname: Ben-Gal fullname: Ben-Gal, Tuvia – sequence: 86 givenname: Cândida surname: Fonseca fullname: Fonseca, Cândida – sequence: 87 givenname: Mehmet Birhan surname: Yilmaz fullname: Yilmaz, Mehmet Birhan – sequence: 88 givenname: Olga surname: Barbarash fullname: Barbarash, Olga – sequence: 89 givenname: José Carlos surname: Nicolau fullname: Nicolau, José Carlos – sequence: 90 givenname: Eduardo Roque surname: Perna fullname: Perna, Eduardo Roque – sequence: 91 givenname: Ramon Luis surname: Corbalan Herreros fullname: Corbalan Herreros, Ramon Luis – sequence: 92 givenname: Kyu-Hyung surname: Ryu fullname: Ryu, Kyu-Hyung – sequence: 93 givenname: Harvey D surname: White fullname: White, Harvey D – sequence: 94 givenname: Lana surname: Tsao fullname: Tsao, Lana – sequence: 95 givenname: Neil Pendril surname: Lewis fullname: Lewis, Neil Pendril – sequence: 96 givenname: Jean surname: Foucauld fullname: Foucauld, Jean – sequence: 97 givenname: Mahfouz surname: El Shahawy fullname: El Shahawy, Mahfouz – sequence: 98 givenname: William J surname: French fullname: French, William J – sequence: 99 givenname: Carsten surname: Schmalfuss fullname: Schmalfuss, Carsten – sequence: 100 givenname: Lily surname: Zhang fullname: Zhang, Lily |
| Copyright | Copyright © 2020 Massachusetts Medical Society. All rights reserved. Copyright © 2020 Massachusetts Medical Society. |
| Copyright_xml | – notice: Copyright © 2020 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2020 Massachusetts Medical Society. |
| CorporateAuthor | SOLOIST-WHF Trial Investigators |
| CorporateAuthor_xml | – name: SOLOIST-WHF Trial Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 ADTPV AOWAS |
| DOI | 10.1056/NEJMoa2030183 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database Medical Database Psychology Database (Proquest) Proquest Research Library Science Database Biological Science Database (ProQuest) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic SwePub SwePub Articles |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 128 |
| ExternalDocumentID | oai_swepub_ki_se_466553 33200892 10_1056_NEJMoa2030183 NJ202101143840207 |
| Genre | Original Article Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | North America Europe Latin America |
| GeographicLocations_xml | – name: Latin America – name: North America – name: Europe |
| GroupedDBID | - 0R 0WA 123 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 9M8 AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAUTI AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACPVT ACRZS ADBBV ADBIT ADCBC AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MQT MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ACKOT ACPFK ADRHT ADUKH AERZD AFFHD AGHSJ BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM AFOSN ALIPV CGR CUY CVF ECM EIF NPM 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO 186 1CY 1KJ 3O- 41~ 6TJ 8WZ A6W AAQOH ABDPE ABEFU ACTDY ADTPV ADXHL AFFDN AJUXI AOWAS D0S EJD FA8 H13 J5H LPU NHB OHT QZG SKT UBX UQL WHG YHZ YQI YQJ YYQ ZGI ZKB ZXP |
| ID | FETCH-LOGICAL-c428t-fa00f50fbc5de8dc92135d9cb95376a603f0ca254e47128e162a9101dd48b7743 |
| IEDL.DBID | DCD |
| ISICitedReferencesCount | 1029 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000609886200011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Tue Nov 25 03:34:29 EST 2025 Fri Sep 05 06:24:44 EDT 2025 Sat Nov 29 14:29:24 EST 2025 Fri Aug 08 01:51:53 EDT 2025 Tue Nov 18 22:36:06 EST 2025 Sat Nov 29 03:02:09 EST 2025 Tue Dec 21 14:38:58 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2020 Massachusetts Medical Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c428t-fa00f50fbc5de8dc92135d9cb95376a603f0ca254e47128e162a9101dd48b7743 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-1278-6245 0000-0001-6896-2941 0000-0003-4596-2791 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2030183?articleTools=true |
| PMID | 33200892 |
| PQID | 2477705048 |
| PQPubID | 40644 |
| PageCount | 12 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_466553 proquest_miscellaneous_2461398731 proquest_journals_2477705048 pubmed_primary_33200892 crossref_primary_10_1056_NEJMoa2030183 crossref_citationtrail_10_1056_NEJMoa2030183 mms_nejm_10_1056_NEJMoa2030183 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-14 |
| PublicationDateYYYYMMDD | 2021-01-14 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2021 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Zelniker, TA, Wiviott, SD, Raz, I (r019) 2019; 393 Tyl, B, Lopez Sendon, J, Borer, JS (r051) 2020; 13 Kumar, N, Garg, A, Bhatt, DL (r038) 2018; 96 Verma, S, Mazer, CD, Bhatt, DL (r042) 2019; 42 Bhatt, DL, Cryer, BL, Contant, CF (r049) 2010; 363 Verma, S, Mazer, CD, Yan, AT (r043) 2019; 140 Neal, B, Perkovic, V, Mahaffey, KW (r005) 2017; 377 Scirica, BM, Braunwald, E, Raz, I (r012) 2014; 130 Hess, DA, Terenzi, DC, Trac, JZ (r036) 2019; 30 Andersen, PK, Angst, J, Ravn, H (r032) 2019; 25 Scirica, BM, Bhatt, DL, Braunwald, E (r010) 2013; 369 Sherman, SE, Bell, GI, Teoh, H (r039) 2018; 3 Damman, K, Beusekamp, JC, Boorsma, EM (r035) 2020; 22 Bhatt, DL, Verma, S, Braunwald, E (r001) 2019; 30 Kato, ET, Silverman, MG, Mosenzon, O (r018) 2019; 139 Packer, M, Anker, SD, Butler, J (r024) 2020; 383 Powell, DR, Zambrowicz, B, Morrow, L (r028) 2020; 105 Cannon, CP, Pratley, R, Dagogo-Jack, S (r022) 2020; 383 Packer, M (r040) 2020; 43 Avogaro, A, Fadini, GP, Del Prato, S (r041) 2020; 43 Gaudino, M, Arvind, V, Hameed, I (r047) 2020; 76 Selvaraj, S, Greene, SJ, Khatana, SAM, Nathan, AS, Solomon, SD, Bhatt, DL (r048) 2020; 9 Wiviott, SD, Raz, I, Bonaca, MP (r007) 2019; 380 Verma, S, Bhatt, DL (r002) 2019; 140 Sands, AT, Zambrowicz, BP, Rosenstock, J (r027) 2015; 38 Perkovic, V, Jardine, MJ, Neal, B (r006) 2019; 380 Buse, JB, Garg, SK, Rosenstock, J (r029) 2018; 41 Green, CP, Porter, CB, Bresnahan, DR, Spertus, JA (r031) 2000; 35 Lin, DY, Wei, LJ (r033) 1989; 84 Opingari, E, Verma, S, Connelly, KA (r044) 2020; 35 Bagiella, E, Bhatt, DL, Gaudino, M (r045) 2020; 76 Steg, PG, Bhatt, DL, Wilson, PW (r016) 2007; 297 Scirica, BM, Braunwald, E, Raz, I (r011) 2015; 132 Cavender, MA, Steg, PG, Smith, SC (r008) 2015; 132 Heerspink, HJL, Stefánsson, BV, Correa-Rotter, R (r021) 2020; 383 Udell, JA, Bhatt, DL, Braunwald, E (r013) 2015; 38 Chowdhury, B, Luu, AZ, Luu, VZ (r037) 2020; 524 Stukel, TA, Glynn, RJ, Fisher, ES, Sharp, SM, Lu-Yao, G, Wennberg, JE (r034) 1994; 13 Vaduganathan, M, Sathiyakumar, V, Singh, A (r020) 2018; 72 Rodbard, HW, Giaccari, A, Lajara, R (r026) Bhatt, DL, Eagle, KA, Ohman, EM (r017) 2010; 304 Scirica, BM, Bhatt, DL, Braunwald, E (r009) 2016; 1 McMurray, JJV, Solomon, SD, Inzucchi, SE (r023) 2019; 381 Jatene, T, Harrington, RA, Stone, GW (r050) 2016; 67 Connelly, KA, Bhatt, DL, Verma, S (r003) 2018; 28 Udell, JA, Cavender, MA, Bhatt, DL, Chatterjee, S, Farkouh, ME, Scirica, BM (r014) 2015; 3 Danne, T, Cariou, B, Banks, P (r030) 2018; 41 Bhatt, DL, Steg, PG, Ohman, EM (r015) 2006; 295 Garg, SK, Henry, RR, Banks, P (r025) 2017; 377 Zinman, B, Wanner, C, Lachin, JM (r004) 2015; 373 Gaba, P, Bhatt, DL (r046) 2020; 17 Tyl B (e_1_3_5_52_2) 2020; 13 Avogaro A (e_1_3_5_42_2) 2020; 43 Bagiella E (e_1_3_5_46_2) 2020; 76 Wiviott SD (e_1_3_5_8_2) 2019; 380 Kumar N (e_1_3_5_39_2) 2018; 96 Udell JA (e_1_3_5_14_2) 2015; 38 Jatene T (e_1_3_5_51_2) 2016; 67 Andersen PK (e_1_3_5_33_2) 2019; 25 Scirica BM (e_1_3_5_13_2) 2014; 130 Hess DA (e_1_3_5_37_2) 2019; 30 Heerspink HJL (e_1_3_5_22_2) 2020; 383 Udell JA (e_1_3_5_15_2) 2015; 3 Zelniker TA (e_1_3_5_20_2) 2019; 393 Zinman B (e_1_3_5_5_2) 2015; 373 Cannon CP (e_1_3_5_23_2) 2020; 383 Perkovic V (e_1_3_5_7_2) 2019; 380 Bhatt DL (e_1_3_5_18_2) 2010; 304 Neal B (e_1_3_5_6_2) 2017; 377 Cavender MA (e_1_3_5_9_2) 2015; 132 Sherman SE (e_1_3_5_40_2) 2018; 3 Verma S (e_1_3_5_3_2) 2019; 140 Damman K (e_1_3_5_36_2) 2020; 22 Kato ET (e_1_3_5_19_2) 2019; 139 Steg PG (e_1_3_5_17_2) 2007; 297 Powell DR (e_1_3_5_29_2) 2020; 105 Lin DY (e_1_3_5_34_2) 1989; 84 Selvaraj S (e_1_3_5_49_2) 2020; 9 Packer M (e_1_3_5_25_2) 2020; 383 Scirica BM (e_1_3_5_12_2) 2015; 132 Chowdhury B (e_1_3_5_38_2) 2020; 524 Scirica BM (e_1_3_5_10_2) 2016; 1 Garg SK (e_1_3_5_26_2) 2017; 377 Stukel TA (e_1_3_5_35_2) 1994; 13 Bhatt DL (e_1_3_5_2_2) 2019; 30 Danne T (e_1_3_5_31_2) 2018; 41 Connelly KA (e_1_3_5_4_2) 2018; 28 Verma S (e_1_3_5_44_2) 2019; 140 Green CP (e_1_3_5_32_2) 2000; 35 Verma S (e_1_3_5_43_2) 2019; 42 Opingari E (e_1_3_5_45_2) 2020; 35 Sands AT (e_1_3_5_28_2) 2015; 38 Vaduganathan M (e_1_3_5_21_2) 2018; 72 Bhatt DL (e_1_3_5_50_2) 2010; 363 McMurray JJV (e_1_3_5_24_2) 2019; 381 Rodbard HW (e_1_3_5_27_2) 2020 Buse JB (e_1_3_5_30_2) 2018; 41 Scirica BM (e_1_3_5_11_2) 2013; 369 Bhatt DL (e_1_3_5_16_2) 2006; 295 Packer M (e_1_3_5_41_2) 2020; 43 Gaba P (e_1_3_5_47_2) 2020; 17 Gaudino M (e_1_3_5_48_2) 2020; 76 33704413 - Eur Heart J. 2021 Apr 14;42(15):1458-1459. doi: 10.1093/eurheartj/ehab136. 33852786 - N Engl J Med. 2021 Apr 15;384(15):1470-1471. doi: 10.1056/NEJMc2102961. 33852787 - N Engl J Med. 2021 Apr 15;384(15):1471. doi: 10.1056/NEJMc2102961. 33950435 - MMW Fortschr Med. 2021 Mar;163(Suppl 1):20-21. doi: 10.1007/s15006-021-9895-6. 33235374 - Nat Rev Cardiol. 2021 Feb;18(2):74. doi: 10.1038/s41569-020-00486-0. 33497553 - N Engl J Med. 2021 Jan 14;384(2):179-181. doi: 10.1056/NEJMe2033176. |
| References_xml | – volume: 41 start-page: 1981 year: 2018 end-page: 1990 ident: r030 article-title: HbA and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study. publication-title: Diabetes Care – volume: 132 start-page: 923 year: 2015 end-page: 931 ident: r008 article-title: Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. publication-title: Circulation – volume: 363 start-page: 1909 year: 2010 end-page: 1917 ident: r049 article-title: Clopidogrel with or without omeprazole in coronary artery disease. publication-title: N Engl J Med – volume: 3 start-page: 327 year: 2018 end-page: 329 ident: r039 article-title: Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia. publication-title: JACC Basic Transl Sci – volume: 17 start-page: 673 year: 2020 end-page: 675 ident: r046 article-title: The COVID-19 pandemic: a catalyst to improve clinical trials. publication-title: Nat Rev Cardiol – volume: 295 start-page: 180 year: 2006 end-page: 189 ident: r015 article-title: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. publication-title: JAMA – volume: 35 start-page: 1245 year: 2000 end-page: 1255 ident: r031 article-title: Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. publication-title: J Am Coll Cardiol – volume: 369 start-page: 1317 year: 2013 end-page: 1326 ident: r010 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. publication-title: N Engl J Med – volume: 373 start-page: 2117 year: 2015 end-page: 2128 ident: r004 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. publication-title: N Engl J Med – volume: 105 start-page: e1235 issue: 4 year: 2020 end-page: e1249 ident: r028 article-title: Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. publication-title: J Clin Endocrinol Metab – volume: 132 start-page: e198 issue: 15 year: 2015 end-page: e198 ident: r011 article-title: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. publication-title: Circulation – volume: 25 start-page: 681 year: 2019 end-page: 695 ident: r032 article-title: Modeling marginal features in studies of recurrent events in the presence of a terminal event. publication-title: Lifetime Data Anal – volume: 76 start-page: 1605 year: 2020 end-page: 1606 ident: r047 article-title: Effects of the COVID pandemic on active non-COVID clinical trials. publication-title: J Am Coll Cardiol – volume: 524 start-page: 50 year: 2020 end-page: 56 ident: r037 article-title: The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. publication-title: Biochem Biophys Res Commun – volume: 42 start-page: e42 year: 2019 end-page: e44 ident: r042 article-title: Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial. publication-title: Diabetes Care – volume: 377 start-page: 2337 year: 2017 end-page: 2348 ident: r025 article-title: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. publication-title: N Engl J Med – volume: 297 start-page: 1197 year: 2007 end-page: 1206 ident: r016 article-title: One-year cardiovascular event rates in outpatients with atherothrombosis. publication-title: JAMA – volume: 41 start-page: 1970 year: 2018 end-page: 1980 ident: r029 article-title: Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study. publication-title: Diabetes Care – volume: 43 start-page: 508 year: 2020 end-page: 511 ident: r040 article-title: SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. publication-title: Diabetes Care – volume: 30 start-page: 609 year: 2019 end-page: 613 ident: r036 article-title: SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. publication-title: Cell Metab – volume: 380 start-page: 2295 year: 2019 end-page: 2306 ident: r006 article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. publication-title: N Engl J Med – volume: 84 start-page: 1074 year: 1989 end-page: 1078 ident: r033 article-title: The robust inference for the Cox proportional hazards model. publication-title: J Am Stat Assoc – volume: 9 start-page: e018274 issue: 18 year: 2020 end-page: e018274 ident: r048 article-title: The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19. publication-title: J Am Heart Assoc – ident: r026 article-title: Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. publication-title: Diabetes Obes Metab – volume: 30 start-page: 847 year: 2019 end-page: 849 ident: r001 article-title: The DAPA-HF trial: a momentous victory in the war against heart failure. publication-title: Cell Metab – volume: 383 start-page: 1425 year: 2020 end-page: 1435 ident: r022 article-title: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. publication-title: N Engl J Med – volume: 13 start-page: 1781 year: 1994 end-page: 1791 ident: r034 article-title: Standardized rates of recurrent outcomes. publication-title: Stat Med – volume: 43 start-page: 501 year: 2020 end-page: 507 ident: r041 article-title: Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. publication-title: Diabetes Care – volume: 35 start-page: 895 year: 2020 end-page: 897 ident: r044 article-title: The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. publication-title: Nephrol Dial Transplant – volume: 383 start-page: 1436 year: 2020 end-page: 1446 ident: r021 article-title: Dapagliflozin in patients with chronic kidney disease. publication-title: N Engl J Med – volume: 96 start-page: 1184 year: 2018 end-page: 1187 ident: r038 article-title: Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. publication-title: Can J Physiol Pharmacol – volume: 72 start-page: 3370 year: 2018 end-page: 3372 ident: r020 article-title: Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. publication-title: J Am Coll Cardiol – volume: 13 start-page: e006720 issue: 7 year: 2020 end-page: e006720 ident: r051 article-title: Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT Heart Failure Study. publication-title: Circ Heart Fail – volume: 140 start-page: 1448 year: 2019 end-page: 1450 ident: r002 article-title: More CREDENCE for SGLT2 inhibition. publication-title: Circulation – volume: 67 start-page: 596 year: 2016 end-page: 598 ident: r050 article-title: Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX trial. publication-title: J Am Coll Cardiol – volume: 38 start-page: 1181 year: 2015 end-page: 1188 ident: r027 article-title: Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. publication-title: Diabetes Care – volume: 76 start-page: 342 year: 2020 end-page: 345 ident: r045 article-title: The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials. publication-title: J Am Coll Cardiol – volume: 381 start-page: 1995 year: 2019 end-page: 2008 ident: r023 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction. publication-title: N Engl J Med – volume: 140 start-page: 1693 year: 2019 end-page: 1702 ident: r043 article-title: Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. publication-title: Circulation – volume: 377 start-page: 644 year: 2017 end-page: 657 ident: r005 article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes. publication-title: N Engl J Med – volume: 380 start-page: 347 year: 2019 end-page: 357 ident: r007 article-title: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. publication-title: N Engl J Med – volume: 304 start-page: 1350 year: 2010 end-page: 1357 ident: r017 article-title: Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. publication-title: JAMA – volume: 22 start-page: 713 year: 2020 end-page: 722 ident: r035 article-title: Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). publication-title: Eur J Heart Fail – volume: 38 start-page: 696 year: 2015 end-page: 705 ident: r013 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. publication-title: Diabetes Care – volume: 393 start-page: 31 year: 2019 end-page: 39 ident: r019 article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. publication-title: Lancet – volume: 139 start-page: 2528 year: 2019 end-page: 2536 ident: r018 article-title: Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. publication-title: Circulation – volume: 130 start-page: 1579 year: 2014 end-page: 1588 ident: r012 article-title: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. publication-title: Circulation – volume: 3 start-page: 356 year: 2015 end-page: 366 ident: r014 article-title: Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. publication-title: Lancet Diabetes Endocrinol – volume: 28 start-page: 813 year: 2018 end-page: 815 ident: r003 article-title: Can we DECLARE a victory against cardio-renal disease in diabetes? publication-title: Cell Metab – volume: 1 start-page: 989 year: 2016 end-page: 998 ident: r009 article-title: Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. publication-title: JAMA Cardiol – volume: 383 start-page: 1413 year: 2020 end-page: 1424 ident: r024 article-title: Cardiovascular and renal outcomes with empagliflozin in heart failure. publication-title: N Engl J Med – volume: 25 start-page: 681 year: 2019 ident: e_1_3_5_33_2 article-title: Modeling marginal features in studies of recurrent events in the presence of a terminal event. publication-title: Lifetime Data Anal doi: 10.1007/s10985-019-09462-4 – volume: 35 start-page: 1245 year: 2000 ident: e_1_3_5_32_2 article-title: Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(00)00531-3 – volume: 3 start-page: 327 year: 2018 ident: e_1_3_5_40_2 article-title: Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia. publication-title: JACC Basic Transl Sci doi: 10.1016/j.jacbts.2018.01.010 – volume: 363 start-page: 1909 year: 2010 ident: e_1_3_5_50_2 article-title: Clopidogrel with or without omeprazole in coronary artery disease. publication-title: N Engl J Med doi: 10.1056/NEJMoa1007964 – volume: 380 start-page: 347 year: 2019 ident: e_1_3_5_8_2 article-title: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1812389 – volume: 42 start-page: e42 year: 2019 ident: e_1_3_5_43_2 article-title: Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial. publication-title: Diabetes Care doi: 10.2337/dc18-1959 – volume: 76 start-page: 1605 year: 2020 ident: e_1_3_5_48_2 article-title: Effects of the COVID pandemic on active non-COVID clinical trials. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.07.051 – year: 2020 ident: e_1_3_5_27_2 article-title: Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. publication-title: Diabetes Obes Metab doi: 10.1111/dom.14127 – volume: 38 start-page: 1181 year: 2015 ident: e_1_3_5_28_2 article-title: Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. publication-title: Diabetes Care doi: 10.2337/dc14-2806 – volume: 381 start-page: 1995 year: 2019 ident: e_1_3_5_24_2 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction. publication-title: N Engl J Med doi: 10.1056/NEJMoa1911303 – volume: 13 start-page: 1781 year: 1994 ident: e_1_3_5_35_2 article-title: Standardized rates of recurrent outcomes. publication-title: Stat Med doi: 10.1002/sim.4780131709 – volume: 295 start-page: 180 year: 2006 ident: e_1_3_5_16_2 article-title: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. publication-title: JAMA doi: 10.1001/jama.295.2.180 – volume: 30 start-page: 609 year: 2019 ident: e_1_3_5_37_2 article-title: SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. publication-title: Cell Metab doi: 10.1016/j.cmet.2019.08.015 – volume: 140 start-page: 1448 year: 2019 ident: e_1_3_5_3_2 article-title: More CREDENCE for SGLT2 inhibition. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.041181 – volume: 393 start-page: 31 year: 2019 ident: e_1_3_5_20_2 article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. publication-title: Lancet doi: 10.1016/S0140-6736(18)32590-X – volume: 43 start-page: 501 year: 2020 ident: e_1_3_5_42_2 article-title: Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. publication-title: Diabetes Care doi: 10.2337/dc19-1410 – volume: 383 start-page: 1425 year: 2020 ident: e_1_3_5_23_2 article-title: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa2004967 – volume: 41 start-page: 1981 year: 2018 ident: e_1_3_5_31_2 article-title: HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study. publication-title: Diabetes Care doi: 10.2337/dc18-0342 – volume: 132 start-page: 923 year: 2015 ident: e_1_3_5_9_2 article-title: Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.114.014796 – volume: 22 start-page: 713 year: 2020 ident: e_1_3_5_36_2 article-title: Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). publication-title: Eur J Heart Fail doi: 10.1002/ejhf.1713 – volume: 105 start-page: e1235 issue: 4 year: 2020 ident: e_1_3_5_29_2 article-title: Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. publication-title: J Clin Endocrinol Metab doi: 10.1210/clinem/dgz258 – volume: 38 start-page: 696 year: 2015 ident: e_1_3_5_14_2 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. publication-title: Diabetes Care doi: 10.2337/dc14-1850 – volume: 43 start-page: 508 year: 2020 ident: e_1_3_5_41_2 article-title: SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. publication-title: Diabetes Care doi: 10.2337/dci19-0074 – volume: 373 start-page: 2117 year: 2015 ident: e_1_3_5_5_2 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 139 start-page: 2528 year: 2019 ident: e_1_3_5_19_2 article-title: Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.040130 – volume: 72 start-page: 3370 year: 2018 ident: e_1_3_5_21_2 article-title: Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.08.2202 – volume: 17 start-page: 673 year: 2020 ident: e_1_3_5_47_2 article-title: The COVID-19 pandemic: a catalyst to improve clinical trials. publication-title: Nat Rev Cardiol doi: 10.1038/s41569-020-00439-7 – volume: 13 start-page: e006720 issue: 7 year: 2020 ident: e_1_3_5_52_2 article-title: Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT Heart Failure Study. publication-title: Circ Heart Fail doi: 10.1161/CIRCHEARTFAILURE.119.006720 – volume: 377 start-page: 2337 year: 2017 ident: e_1_3_5_26_2 article-title: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1708337 – volume: 524 start-page: 50 year: 2020 ident: e_1_3_5_38_2 article-title: The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2020.01.015 – volume: 140 start-page: 1693 year: 2019 ident: e_1_3_5_44_2 article-title: Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.042375 – volume: 304 start-page: 1350 year: 2010 ident: e_1_3_5_18_2 article-title: Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. publication-title: JAMA doi: 10.1001/jama.2010.1322 – volume: 84 start-page: 1074 year: 1989 ident: e_1_3_5_34_2 article-title: The robust inference for the Cox proportional hazards model. publication-title: J Am Stat Assoc doi: 10.1080/01621459.1989.10478874 – volume: 76 start-page: 342 year: 2020 ident: e_1_3_5_46_2 article-title: The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.05.041 – volume: 35 start-page: 895 year: 2020 ident: e_1_3_5_45_2 article-title: The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfz294 – volume: 297 start-page: 1197 year: 2007 ident: e_1_3_5_17_2 article-title: One-year cardiovascular event rates in outpatients with atherothrombosis. publication-title: JAMA doi: 10.1001/jama.297.11.1197 – volume: 41 start-page: 1970 year: 2018 ident: e_1_3_5_30_2 article-title: Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study. publication-title: Diabetes Care doi: 10.2337/dc18-0343 – volume: 369 start-page: 1317 year: 2013 ident: e_1_3_5_11_2 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. publication-title: N Engl J Med doi: 10.1056/NEJMoa1307684 – volume: 383 start-page: 1436 year: 2020 ident: e_1_3_5_22_2 article-title: Dapagliflozin in patients with chronic kidney disease. publication-title: N Engl J Med doi: 10.1056/NEJMoa2024816 – volume: 9 start-page: e018274 issue: 18 year: 2020 ident: e_1_3_5_49_2 article-title: The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19. publication-title: J Am Heart Assoc doi: 10.1161/JAHA.120.018274 – volume: 67 start-page: 596 year: 2016 ident: e_1_3_5_51_2 article-title: Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX trial. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.11.027 – volume: 30 start-page: 847 year: 2019 ident: e_1_3_5_2_2 article-title: The DAPA-HF trial: a momentous victory in the war against heart failure. publication-title: Cell Metab doi: 10.1016/j.cmet.2019.10.008 – volume: 96 start-page: 1184 year: 2018 ident: e_1_3_5_39_2 article-title: Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. publication-title: Can J Physiol Pharmacol doi: 10.1139/cjpp-2018-0359 – volume: 383 start-page: 1413 year: 2020 ident: e_1_3_5_25_2 article-title: Cardiovascular and renal outcomes with empagliflozin in heart failure. publication-title: N Engl J Med doi: 10.1056/NEJMoa2022190 – volume: 28 start-page: 813 year: 2018 ident: e_1_3_5_4_2 article-title: Can we DECLARE a victory against cardio-renal disease in diabetes? publication-title: Cell Metab doi: 10.1016/j.cmet.2018.11.010 – volume: 377 start-page: 644 year: 2017 ident: e_1_3_5_6_2 article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1611925 – volume: 132 start-page: e198 issue: 15 year: 2015 ident: e_1_3_5_12_2 article-title: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. publication-title: Circulation – volume: 130 start-page: 1579 year: 2014 ident: e_1_3_5_13_2 article-title: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.114.010389 – volume: 1 start-page: 989 year: 2016 ident: e_1_3_5_10_2 article-title: Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2016.3030 – volume: 3 start-page: 356 year: 2015 ident: e_1_3_5_15_2 article-title: Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(15)00044-3 – volume: 380 start-page: 2295 year: 2019 ident: e_1_3_5_7_2 article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. publication-title: N Engl J Med doi: 10.1056/NEJMoa1811744 – reference: 33704413 - Eur Heart J. 2021 Apr 14;42(15):1458-1459. doi: 10.1093/eurheartj/ehab136. – reference: 33852787 - N Engl J Med. 2021 Apr 15;384(15):1471. doi: 10.1056/NEJMc2102961. – reference: 33497553 - N Engl J Med. 2021 Jan 14;384(2):179-181. doi: 10.1056/NEJMe2033176. – reference: 33950435 - MMW Fortschr Med. 2021 Mar;163(Suppl 1):20-21. doi: 10.1007/s15006-021-9895-6. – reference: 33235374 - Nat Rev Cardiol. 2021 Feb;18(2):74. doi: 10.1038/s41569-020-00486-0. – reference: 33852786 - N Engl J Med. 2021 Apr 15;384(15):1470-1471. doi: 10.1056/NEJMc2102961. |
| SSID | ssj0000149 |
| Score | 2.746174 |
| Snippet | Patients with diabetes and recent worsening heart failure that had led to hospitalization were randomly assigned to receive sotagliflozin or placebo. At a... Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with... BackgroundSodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among... |
| SourceID | swepub proquest pubmed crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 117 |
| SubjectTerms | Acute Kidney Injury - chemically induced Aged Cardiac arrhythmia Cardiovascular Diseases - epidemiology Cardiovascular Diseases - mortality Congestive heart failure Corporate sponsorship Death Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diarrhea Diuretics Double-Blind Method Ejection fraction Female Glucose Glycosides - adverse effects Glycosides - therapeutic use Heart failure Heart Failure - complications Heart Failure - drug therapy Hospitalization Hospitalization - statistics & numerical data Humans Hypoglycemia Hypotension Hypotension - chemically induced Male Middle Aged Peptides Placebos Sodium-glucose cotransporter Sodium-Glucose Transporter 1 - antagonists & inhibitors Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Statistical analysis |
| SummonAdditionalLinks | – databaseName: Biological Science Database (ProQuest) dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB6apJRcmvS9zQMVSk81sSXLlk6llCyhtGGhr9yMJEuw7a6drDc99Nd3xtZum5LkUvDBWHMYPDOaJ98AvDToY5zDtMQWViV5UajEFCIkNmiLV7KQrscp-PqhPD1VZ2d6EgtuXRyrXN2J_UVdt45q5Ec8L8sylahwb84vEtoaRd3VuEJjA7YIJUH0o3uTv-CjYvgbK0gRYxN9_hFtmm8Np4RAiSs-aWM-764LN__BEu39z3jnfznfhfsx8mRvB1V5AHd88xDufYy99Ufw_hN1qGbTMGt_TRuGz2TAXO0YFWtZnJ3pmGlqhtEmnrBv7aLzVFlhJ2gxSzY2Uxpzfwxfxsef350kcdNC4jD9WCbBpGmQabBO1l7VTvNMyFo7qwntxRSpCKkzmEt69GVc-azgBuOMrK5zZTGAFE9gs2kb_wyYkWWwsqhTHnyeawJ451KV1qiAwanRI3i9-teVizDktA1jVvXtcFlUV0Qzgldr8vMBf-MmwkMUXNX47_ObCPZX4qminXbVH9mM4MX6GC2M2iam8e0l0WDIo1UpshE8HXRhzYoQND-iObI5KMf6hGC746cf-OYrtAMpxfPbudiDbU5DM2mWZPk-bC4Xl_4A7rqfy2m3OOy1-zcTBf7f priority: 102 providerName: ProQuest |
| Title | Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa2030183 https://www.ncbi.nlm.nih.gov/pubmed/33200892 https://www.proquest.com/docview/2477705048 https://www.proquest.com/docview/2461398731 http://kipublications.ki.se/Default.aspx?queryparsed=id:145772735 |
| Volume | 384 |
| WOSCitedRecordID | wos000609886200011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELbWDaG98BtWGJWREE9ES-w4th-hWzUhWqoyRt8ix7GlQpugpuOBv567xK0YMCGk6FMUO9LJPseffc53hLw0MMdYC8uSIitUlGaZikzGfVR4XcAnmQvb6hRcvpeTiZrP9XSPnGz_hancl1UbwMcRjTvQ2-zwJ5gbvjYMKbziPXIAvqYxV8Pp8PQXvajAd8OWURDV_OP1a5NQb7Vq_sYvfxMPbSec0d3_NvUeuRO4JX3TOcN9sueqB-T2OETPH5J3HzEGtVz4Zf1jUVG4pp2qakNxO5aG0zENNVVJgU9CCf1crxuHeyf0HMbEho7MAg-yPyKfRmcXw_Mo5FKILCwwNpE3cexF7AsrSqdKq1nCRaltoVHPxWQx97E1sFp0MFsx5ZKMGWASSVmmqgCKyB-T_aqu3BGhRkhfiKyMmXdpqlHCnQklC6M80E-j--T1tnFzG4TGMd_FMm8D3iLLr7VPn7zaVf_WKWzcVHEAPZVjs99U4XjbiXkYiU3OUillLOBD1ScvdsUwhjAwYipXX2EdIDVaSZ70yZOu83emcI4nRDQDMztv2JWgMHd49BXuXA6eLgR_-i8zn5FDhgdj4iRK0mOyv1lfuefklv2-WTTrAenJ2SXiXLaoANUwGZCDt2eT6WzQOjzgOJ61eIHIxi1-aHGKKKc_ARIr-P0 |
| linkProvider | Massachusetts Medical Society |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB21BVEufH8slGIk4ETUxIkT54AQAlZburuqxEJ7C45jS1t2k7LZguBH8RuZSZyFIsqtB6QcotiK7Ph5_DyevAF4rHCN0Rq3JXmcSy-KY-mpOLRebtMcTXIodKNT8GGYjMfy8DDdX4Mf3b8wFFbZ2cTGUBeVJh_5Do-SJPEFAu7F8WePskbR6WqXQqOFxZ759hW3bPXz3dc4vk8477-ZvBp4LquAp5FqLz2rfN8K3-ZaFEYWOuVBKIpU5ykpm6jYD62vFe6bDNptLk0Qc4VralAUkcyRLIX43nW4QLp6FEI48ie_yVU5uu08Vk7TEznGDmW2rxSnDYgMT62B6_N5_Td6-4d2abPe9a_-b1_qGlxxzJq9bKfCdVgz5Q24NHKxAzfh7Ts6gZtN7az6Pi0ZXvutpmzNyBnNXGxQzVRZMGTTWMIOqkVtyHPEBtihJeurKYXx34L359KT27BRVqW5C0yJxOYiLnxuTRSlJGDPhUxyJS2Sb5X24Fk3tpl2MuuU7WOWNcf9Is5OQaEHT1fVj1t9kbMqbiNQstIczc-qsNXBIXN2qM5-YaEHj1bFaEHoWEiVpjqhOkjpUpmEQQ_utNhbNSUMKT4m5djMFoyrEpIld48-4Z3JcJ4LEd77dysewuZgMhpmw93x3n24zClAyA-8INqCjeXixDyAi_rLclovtpuZxeDjeQP0JxfSWts |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BVVceD8WSjEScCJqYseJc0AItaxaWlYr8eotdRxbWthNymYLgp_Gr2MmcRaKKLcekHKIYiuyk8_jz-PxNwCPNM4xxuCypEgKFcRJogKdCBcULivQJAtpWp2C9wfpaKQOD7PxCvzoz8JQWGVvE1tDXdaGfORbPE7TNJQkM-t8WMR4Z_j8-HNAGaRop7VPp9FBZN9--4rLt-bZ3g7-68ecD1--3d4NfIaBwCDtXgROh6GToSuMLK0qTcYjIcvMFBmpnOgkFC40GtdQFm04VzZKuMb5NSrLWBVInAS-dxUupAJRTKfUt6PfpKs89fbeK6_viXxji7Lc15rTYkSJU_Ph6mzW_I3q_qFj2s59wyv_81e7Cpc942YvuiFyDVZsdR3WX_uYghvw6g3tzE0nblp_n1QMr3GnNdswclIzHzPUMF2VDFk2lrAP9byx5FFiu9ihBRvqCYX334R359KTW7BW1ZW9A0zL1BUyKUPubBxnJGzPpUoLrRyScp0N4Gn_n3Pj5dcpC8g0b8MAZJKfgsUAniyrH3e6I2dV3ETQ5JX9ODurwkYPjdzbpyb_hYsBPFwWo2Wh7SJd2fqE6iDVy1QqogHc7nC4bIoQFDeTcWxmB8xlCcmV-0ef8M7mOP6lFHf_3YoHsI64zA_2Rvv34BKnuKEwCqJ4A9YW8xN7Hy6aL4tJM99sBxmDo_PG50_0wWNZ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sotagliflozin+in+Patients+with+Diabetes+and+Recent+Worsening+Heart+Failure&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Bhatt%2C+Deepak+L&rft.au=Szarek%2C+Michael&rft.au=Steg%2C+P.+Gabriel&rft.au=Cannon%2C+Christopher+P&rft.date=2021-01-14&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=384&rft.issue=2&rft.spage=117&rft.epage=128&rft_id=info:doi/10.1056%2FNEJMoa2030183&rft.externalDocID=NJ202101143840207 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |